Serum urate lowering with allopurinol and kidney function in type 1 diabetes by Doria, Alessandro et al.

Doria A, Galecki A, Spino C, et al. Serum Urate Lowering with Allopurinol and Kidney 
Function in Type 1 Diabetes 
 
This supplement contains the following items 
1. Original protocol (v6 dated December 17, 2013; this was the first protocol version under 
which participants were recruited for the pivotal trial; previous versions were for 
designing purposes only).  
2. Final protocol (v10 dated March 6, 2018). 
3. List of all protocol changes from original to final version. 
4. Original statistical analysis plan (dated February 22, 2017). 
5. Final statistical analysis plan (dated August 3, 2019). 



























































































































































































































































































































































































































































































































































































































































































Summary of Changes to PERL Protocols 
 
NOTE. Version 6 of the protocol (dated December 17, 2013) is the first protocol version under which participants were enrolled in the PERL pivotal 
gainst which subsequent versions are compared.  Protocol versions before v6 were 
for study design purposes only.  
 
# Location Change Rationale 
List of changes to Version 7.0 Amendment 2 July 14, 2014 
p.1 Title page  
 
Change version and date Version 7.0 Amendment 2 July 14, 2014                         
 
Updates to title page 
  Program Officers  
Teresa Jones, MD 
Division of Diabetes, Endocrinology, & Metabolic Diseases 
NIDDK, National Institutes of Health 
6707 Democracy Blvd. Room 609 
Bethesda, MD   20892-5460 
Phone: (301) 435-2996 
Fax: (301) 480-3503 
jonester@mail.nih.gov 
New Project Officer 
p.3 General Information Sponsor for IND #115313 
Alessandro Doria, MD PhD MPH  
Joslin Diabetes Center and Harvard Medical School 
One Joslin Place 
Boston, MA 02215 
Phone (617) 309-2406 
Fax (617) 309-2667 
alessandro.doria@joslin.harvard.edu 
Identify new Sponsor 
p.3 Directors of Clinical Sites 
 
Mount Sinai Hospital 
Room L5-210, Mail Box 16 
60 Murray St. 
Toronto, ON 
Canada, M5G 1X5 
Phone: (416) 586-8763 
Fax: (647) 826-1528 
bruce.perkins@mtsinai.ca 
Change of information 
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p.3 Directors of Clinical Sites 
 
Rodica Pop-Busui, MD PhD 
Associate Professor of Internal Medicine Metabolism, Endocrinology and 
Diabetes 
University of Michigan 
5329 Brehm Tower 
1000 Wall Street 
Ann Arbor MI 48105 
Phone: (734) 763-3056 
rpbusui@umich.edu 
Change of information 
p.4 Directors of Clinical Sites 
 
Janet McGill, MD 
Washington University School of Medicine 
660 S. Euclid, Campus Box 8127 
St. Louis, MO  63110 
Phone: (314) 362-8681 
Fax: (314) 362-4833 
hmcgill@dom.wustl.edu 
 
New Investigator  
p.4  Global Clinical 
Coordinator 
Debbie Conboy, RN CDE  
 
Revise listing 
p.6 PROTOCOL SUMMARY 
Inclusion Criteria 
Criteria 4:                                                                                                                  







Increase screening urinary albumin excretion rates [AERs] or albumin 
creatinine ratios [ACRs] 30-5000 mg/24 hr (20- 5000 mg/g 
range, if not on RASB agents 
OR 
18-5000 mg/24 hr (12- 5000 mg/g range, if on RASB 
agents  
 
Clarify that creatinine measurement is derived from serum 
Age limit raised to include 
patients diagnosed with T1D at 
an age older than 35, who may 
now be in the study based on 
the previous amendment. 
 
The Steering Committee 








May increase the eligible 
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Criteria 6: 
Decrease Estimated GFR (eGFR) based on serum creatinine to between 40 and 
99.9 ml/min/1.73 m2 at screening 
population.  
p.7.  PROTOCOL SUMMARY 
Exclusion Criteria 
Criteria 9: 
Increase:  SBP>150 or DBP>95 mmHg at the end of the run-in period. 
Raising the BP criterion at the 
end of the run-in period will 
facilitate retention in the study 
p.8 PROTOCOL SUMMARY 
Study Duration 
Increase:  acceptable BP 140/90 mmHg  
p.8 PROTOCOL SUMMARY 
Date of Protocol 
Change: July  7, 2014 
 
 
p.12 4. PARTICIPATING 
CENTERS  
 
Increase: in number of centers to nine 
Add: Washington University (St. Louis, MO)  
 
New site assist to enhance 
recruitment 
p.13. 4. PARTICIPATING 
CENTERS 
4.1 Location of study 
visits 
Delete: (Visit 2 and all the visits including an iohexol-GFR measurement, i.e., 
-  
Delete: Study procedures that require physical interactions (e.g., BP 
clinical laboratories close to where participants live (hereby referred to as 
 
 
Insert: Blood draws and urine collections scheduled at the time of Phone Visits 
will be performed at local facilities close to where participants live (hereby 
be conducted remotely, a Phone Visit and a Remote Biospecimen Collection 
will be both required. 
 
Delete: For any given study visit to be conducted remotely, a Phone Visit and a 
Remote Visit will be both required 
 
Insert: Phone Visits and Remote Biospecimen Collections 
 
Insert: Study Site  
 




# Location Change Rationale 
p.14 4. PARTICIPATING 
CENTERS 
4.1 Location of study 
visits 
Insert: Following a Phone Visit, participants may be invited to an In-Person 
facilities if procedures that require physical interactions are deemed to be 
necessary (e.g., BP measurement to confirm the self-report of elevated BP 
values, physical exam to confirm the self report of skin rash). Sites for remote 
in-person visits will be 
personnel will discuss study requirements with the remote site health providers 
and operators and will provided with written instructions on how to carry out 
the procedures that will be conducted at their locations and report the results to 
the Study Site.   
 
Revised structure of Remote 
Visits  
p.14 4. PARTICIPATING 
CENTERS 
4.1 Location of study 
visits 
Delete: Remote Visits text as follows 
Remote Visits will be scheduled as close as possible to the 
corresponding Phone Visit and within the same time window as outlined in 
Section 8.1 
Remote Visits will take place only after a signed copy of the ICF has 
been received by the study site (see Point #2 under Phone Visits). 
Sites for Remote Visits will be chosen by the Study Site based on the 
qualifications.  More than one remote site may be selected for a given visit if 
different procedures must be carried out at different facilities (e.g., if the PCP 
office and Clinical Laboratory are not part of the same structure or institution). 
Study personnel will discuss study requirements with the remote site 
health providers and operators and will provided be with written instructions on 
how to carry out the study procedures that will be conducted at their locations. 
healthcare facilities, clinical laboratories) will include: 
Weight and height measurements. 




Blood draws for local lab tests (serum creatinine, K, and ALT, CBC, pregnancy 
tests). 
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Blood draw for central lab tests (serum creatinine, Cystatin C, uric acid, and 
HbA1c). 
Collection of urine samples from first morning voids (Visit 1) or overnight 
collections (Visits 3, 9, 13, and 15).  
Data (#5a-5e above) will be collected on forms provided by the Study Site and 
will be transmitted back to the Site by fax or other secure methods 
p.14 4. PARTICIPATING 
CENTERS 
4.1 Location of study 
visits 
Insert: Remote Biospecimen Collections 
Local sites for Remote Biospecimen Collections will be chosen by the 
 
Revised procedure for Remote 
Visits specimen collection, 
handling and shipping. 
p.15 4. PARTICIPATING 
CENTERS 
4.1 Location of study 
visits 
Revise: text related to Remote Biospecimen Collection as follows  
Specific instructions will be provided for presentation to the local lab 
sites for specimen collection, handling and tube labeling for specimens 
requiring shipment to the Study Main site Central Laboratory.  Pre-addressed 
shipping containers will also be provided for these Remote Visits along with a 
labeled an inventory sheet for each shipping container will also be provided 
faxing to the Study Main Site or Central Laboratory and inclusion with the 
shipment. 
Blood samples for local lab tests (serum creatinine, K, and ALT, CBC, 
pregnancy tests) will be processed and analyzed at the remote site  facilties 
where samples are collected or shipped to commercial laboratories for testing. 
Results will be transmitted to the Study Site by fax or other secure methods. 
Blood and urine samples for central lab tests (serum creatinine, Cystatin 
C, uric acid, HbA1c, urinary ACR and AER) will be mailed by the Remote Site 
to the Central Lab a commercial lab or to the Main Study Site where they will 
be processed, aliquoted, and forwarded to the Central Lab.  Blood tubes and 
urine containers will be provided by the Study Site. 
 
Revised procedure for specimen 
of Remote Visits collection, 
handling, shipping. 
p.15 5. SUBJECT 
SELECTION 
Inclusion Criteria  
Text revised to be consistent with changes identified in the Protocol Summary 
Subject Population Inclusion Criteria 
Consistency 
p.16 5. SUBJECT 
SELECTION 
Exclusion Criteria 
Text revised to be consistent with changes identified in the Protocol Summary 
Subject Population Exclusion Criteria  
Consistency 
p.20 7. STUDY OUTCOMES   Correct spelling:  insulin   
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PROCEDURES Figure 1.  
Schedule of Events 
Revised to reflect protocol changes in study evaluations and footnotes  The schedule has been revised 
to incorporate the protocol 
changes. 
 
p.25 8. STUDY 
PROCEDURES 
8.2 Screening and 
Enrollment in the Run-in 
Period (Visit 1) 
Revised text: 
Subjects who have a confirmed history of micro- or macroalbuminuria (at least 
two out of three consecutive urinary AER or ACR in micro- or 
macroalbuminuria range as defined in Section 5.1) will not need to bring a 
sample of urine to Visit 1 (if the evidence of micro- or macroalbuminuria dates 
back to more than two years before screening, evidence of ongoing GFR 
decline should be gathered, see Section 5.1). Subjects who have incomplete 
evidence of micro- or macroalbuminuria (one of the last two urinary AER or 






8.3 Screening and 
Enrollment in the Run-in 
Period (Visits 2,3,4) 
RAS antagonist treatment will be standardized, and BP, if elevated (>1430/90 
ysicians 
informing them about the study and notifying them of the study's protocol RAS 
blocker requirements and blood pressure goals. The letter will propose active 
participation of the 
the availability of advice from the PERL site physicians and, if needed, the 
PERL Drug monitoring Committee for out of range blood pressure values 
physicians informing them about the study and notifying them that study 
therapy.  The run-in period will start at Visit 2.  If a participant is already on a 
RAS Blocker, its dose will be increased adjusted, if necessary, to make it at 
least equivalent to ramipril 10 mg (if on ACE inhibitor [ACEI]) or irbesartan 
300 mg (if on an angiotensin receptor blocker [ARB]), if acceptable to the 
below).  Participants who were not taking a RAS Blocker will be prescribed and 
instructed to start taking 10 mg of ramipril daily or 300 mg of irbesartan daily 
(if ramipril is contraindicated or has side effects) or another ACE inhibitor or 
ARB at equivalent doses if there are impediments to the use of ramipril or 
irbesartan. Participants who have contraindications to RAS blockers (e.g., 
Antihypertensive therapy 
should now be managed jointly 


















# Location Change Rationale 
SBP<100 mmHg, K+>5.5 mEq) or are normoalbuminuric and normotensive 
and are not currently treated with RAS blockers, will not be treated with these 
drugs, as this represents the standard of care.  
p26-27 8. STUDY 
PROCEDURES 
8.3 Screening and 
Enrollment in the Run-in 
Period (Visits 2,3,4) 
Revised text:  
If BP is found to be elevated (>1430/980 mm Hg) on three consecutive 
occasions, the dosage of existing non-RAS antagonists antihypertensive drugs 
will be maximized, followed, if necessary, by the introduction of 
antihypertensive drugs of a different class. These will be chosen by the study 
site physicians in collaboration with the other health care providers that are 
-hypertensive therapy. from a 
restricted menu of approved medications at recommended dosage, following the 
general protocol that was used in RASS33.  The same menu and protocol will 
be used to start antihypertensive treatment in participants who have persistently 
high BP levels and were not on antihypertensive therapy prior to study entry.  If 
the goal of BP (>1430/980 mm Hg) is not achieved with these drugs, a Drug 
Monitoring Committee conference call will be convened to consider the 
possibility of causes of hypertension other than diabetic nephropathy and 
discuss alternative therapeutic approaches.  BP will continue to be monitored 
and the anti-hypertensive therapy to be adjusted in a similar way throughout the 
study.      
 
Revised Visit Procedures list:  
After 2 weeks of run-in, participants will come in for Visit 3 during which they 
will undergo the following procedures: 
Review RASB and adjust BP therapy. 
Measure weight and vital signs. 
After 6 weeks of run-in, participants will come in for Visit 4 during which they 
will undergo the following procedures: 
Review RASB and adjust BP therapy 
If normal blood pressure control is not achieved at Visit 4, the run-in period 
may be extended for two more weeks after which participants will be examined 
as in Visit 4 (Visit 4A).  In this event, the GFR measurement scheduled for 
Visit 4 will be conducted at Visit 4A.  Participants whose SBP is >15040 or 
whose DBP is >9590 mmHg at the end of the run-in period will be discontinued 
from the study (prior to randomization). 
 
Antihypertensive therapy 
should now be managed jointly 












The procedure schedule has 
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p.28 8. STUDY 
PROCEDURES 
8.5 Treatment Period 
(Visits 6-15)  
Revise procedures list: 
Obtain interval medical history (with special emphasis on BP control and CVD 
events). 
Review of concomitant medications and AEs.   
Review and adjust RASB and BP therapy. 
Measure height,  (Visits  and 11) weight, and vital signs according to the 
schedule outlined in Figure 1 
Inspect for skin rash  (Visit 11) 
The procedure schedule has 
been revised to incorporate the 
protocol changes. 
p.28  8. STUDY 
PROCEDURES 
8.6  End of Intervention 
(Visit 16)  
Revise procedure list:  
Review RASB and adjust BP therapy. 
 
  
The procedure schedule has 
been revised to incorporate the 
protocol changes. 
 
p.30 9. SAFETY 
ASSESSMENTS 
9.2 Skin Exam 
Revised text: 
At each visit study on and after Visit 4, The skin of study participants will be 
examined for the presence of any kind of rash at each in-person visit.  
Participants will be instructed to carry-out periodical skin self-exams. If skin 
abnormalities are reported to the study personnel during the phone visits or on 
any other occasion, participants will be asked to immediately report to the study 
-person skin 
exam. 
Reflect change in remote visit 
schedule. 
p.30 9. SAFETY 
ASSESSMENTS 
9.3 Vital Signs 
Revised text: 
Blood pressure and heart rate will be recorded at each in-person visit.  BP 
readings at home will be reviewed during each phone visits; if abnormal values 
or other local healthcare facilities to have their BP measured 
Antihypertensive therapy 
should now be managed jointly 
by the study physicians and the 
physicians 
p.42 13.  PROTECTION OF 
HUMAN SUBJECTS 
13.5.b.k. Procedures for 
protecting against and 





Blood pressure will be measured quarterly with the goal of maintaining BP 
be performed within 2 weeks and if still elevated additional antihypertensive 
non-
physicians from a limited menu of agents as prescribed in the MOO.  Failure to 
achieve satisfactory BP control within 2 months would lead to a Drug 
asked to relinquish BP management to PERL personnel in order to achieve 
Reflects change related to 
acceptable BP level 
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medication changes. 
List of Changes in PERL Protocol Version 8.0 November 18, 2014 
p.1 Title page  
 
Change version and date Version 8.0 Approved by the DSMB November 18, 2014       
 
Version date changed to date of 
DSMB approval 
p.2-4 Table of Contents  Page numbers 8-49 changed Page numbers shifted. 
p.7 Directors of Clinical Sites Ronald J. Sigal, MD, MPH 
Cumming School of Medicine, University of Calgary 
1820 Richmond Road SW 
Calgary, Alberta, Canada T2T 5C7 
Phone: (403) 955-8327 
Fax: (403) 955-8249 
rsigal@ucalgary.ca 
New Investigator 
p.7 Directors of Clinical Sites 
 
Peter Senior, MD 
Alberta Diabetes Institute 
2-004 Li Ka Shing Center for Health Research Innovation 
Edmonton, Alberta, Canada T6G2E1 
Phone: (780) 407-1480 
Fax: (780) 492-9555 
petersenior@ualberta.ca 
New Investigator 
p.7-8 Directors of Clinical Sites 
 
Guillermo E. Umpierrez, MD 
Emory University School of Medicine 
101 Wodruff Circle, 1st Floor, RM 1311 
Atlanta, GA 30322 
Phone: (404) 778-1663 
geumpie@emory.edu 
New Investigator 
p.8 Directors of Clinical Sites 
 
Irl B. Hirsch, MD 
University of Washington Medical Center  Roosevelt 
4245 Roosevelt Way, NE, 3rd floor, Box 354691 
Seattle, WA  98105 
Phone:  (206) 598-4884 
Fax:  (202) 598-4976 
ihirsch@uw.edu 
New Investigator  
p.9  PROTOCOL SUMMARY 
Subject Population  
Inclusion/Exclusion Criteria 
Revised Text: 
The upper and the lower limits should be decreased by 1 ml/min/1.73 m2 for each 
year over age 60 (with a lower limit of 35 ml/min/1.73m2) and by 10 ml/min/1.73 m2 
for strict vegans. 
Change in Inclusion criteria to 
reflect changes of eGFR with age 
10 
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p.11 PROTOCOL SUMMARY 
Study Duration 
Revised Text: 
9-week run-in period, during which RAS inhibition will be introduced and/or 
standardized, if indicated, and BP normalized, if elevated above 140/90 mmHg, 
followed by a 3-year treatment period and then by a 2-month wash-out period. 
 
Modification of visit schedule to 
acknowledge that some patients 
enter without the need for RAS 
treatment 
p.11 PROTOCOL SUMMARY 
Date of Protocol 
Revised Text: 
November 18. 2014 
Date approved by DSMB 
p.16 Participating centers New Text: 
University of Calgary (Calgary, Alberta, Canada) 
Alberta Diabetes Institute (Edmonton, Alberta, Canada) 
Emory University (Atlanta) 
University of Washington Medical Center (Seattle) 
New sites added to enhance 
recruitment 
p.18 5. SUBJECT SELECTION 
Inclusion Criteria 
Revised Text: 
The upper and the lower limits should be decreased by 1 ml/min/1.73 m2 for each 
year over age 60 (with a lower limit of 35 ml/min/1.73m2) and by 10 ml/min/1.73 m2 
for strict vegans. 
Change in inclusion criteria to 
reflect changes of eGFR with age 
p.22 6. STUDY TREATMENTS 
6.1.2  Dosage 
New text: 
4. At some sites the study medication may be dispensed directly to the study 
participant at a relevant in person study visit or by mail from the site following a 
relevant in-person or phone study visit. 
Change in study medication 
dispensing 
p.26 8. STUDY PROCEDURES  
Figure 1.  Schedule of 
Events 
Revised Figure 1:                                                                                                                  
To reflect protocol changes in study evaluations and footnotes  
The schedule has been revised to 
incorporate the protocol changes. 
 
p.27 8. STUDY PROCEDURES 
8.3 Run-in Period (visits 2, 3 
and 4) 
Revised Text: 
Starting at Visit 2, eligible subjects who agree to participate in the study will enter a 
run-in period of 9 weeks (see note at the end of this section for exceptions to this 
duration).  During this visit, subjects will undergo the following procedures: 
Reference to modification of 
number of run-in study visits  and 
consequent duration of run-in 
period 
p.28 8. STUDY PROCEDURES 
8.3 Run-in Period (visits 2, 3 
and 4) 
Revised Text: 
RAS antagonist treatment will be standardized, and BP, if elevated (>140/90 mm Hg), 
about the study and notifying them of the study's protocol RAS blocker requirements 
and blood pressure goals. The letter will propose active participation of the 
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from the PERL site physicians and, if needed, the PERL Drug monitoring Committee 
for out of range blood pressure values during the course of the study. The run-in period 
will start at Visit 2.  If a participant is already on a RAS Blocker, its dose will be 
increased, if necessary, to make it at least equivalent to ramipril 10 mg (if on ACE 
inhibitor [ACEI]) or irbesartan 300 mg (if on an angiotensin receptor blocker [ARB]), 
(see below).  Participants who were not taking a RAS Blocker will be prescribed and 
instructed to start taking 10 mg of ramipril daily or 300 mg of irbesartan daily (if 
ramipril is contraindicated or has side effects) or another ACE inhibitor or ARB at 
equivalent doses if there are impediments to the use of ramipril or irbesartan. 
Participants who have contraindications to RAS blockers (e.g., SBP<100 mmHg, 
K+>5.5 mEq) or do not have evidence or history of micro- or macroalbuminuria 
(as defined in 5.1.4), are normotensive, and are not being treated with RASB or 
other anti-hypertensive agents will not be treated with these drugs, as this represents 
the standard of care. 
 
p.28 8. STUDY PROCEDURES 
8.3 Run-in Period (visits 2, 3 
and 4) 
Revised Text: 
After 2 weeks of run-in, participants will come in for Visit 3 during which they will 
undergo the following procedures: 
Obtain interval medical history (with special emphasis on CVD events). 
Review concomitant medications and AEs 
Review RASB and BP therapy. 
Collect samples for clinical laboratory assessments as outlined in Figure 1. 
Perform pregnancy test in women of childbearing potential. 
Be provided with a container and instructions for an overnight urine 
collection to be made immediately before Visit 4. 
 
Delete Text: 
(including HLA B*58.01) in collection of samples for clinical laboratory assessments 
procedures list  
Modification of visit procedure 
list, to exclude collection of HLA 
B*58.01 at this visit 
p.29 8. STUDY PROCEDURES 
8.3 Run-in Period (visits 2, 3 
and 4) 
Revised Text: 
After 6 weeks of run-in, participants will come in for Visit 4 during which they will 
undergo the following procedures: 
 Obtain interval medical history (with special emphasis on CVD events). 
 Conduct a physical exam (if deemed to be required by the study physician) 
 Review concomitant medications and AEs 
 Review BP therapy. 
Modification of visit procedure list 
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 Review the fetal risks of RAS blockade.  
 Measure height, weight and vital signs. 
 Perform ECG. 
 Collect samples for clinical laboratory assessments (including HLA B*58:01)   
as outlined in Figure 1. 
 Perform pregnancy test in women of childbearing potential. 
 Measure iohexol GFR. 
 
p.29 8. STUDY PROCEDURES 
8.3 Run-in Period (visits 2, 3 
and 4) 
New Text: 
If normal blood pressure control is not achieved at Visit 4, the run-in period may be 
extended for two more weeks after which participants will be examined as in Visit 4 
(Visit 4A).  In this event, the GFR measurement scheduled for Visit 4 will be 
conducted at Visit 4A.  Participants whose SBP is >150 or whose DBP is >95 mmHg 
at the end of the run-in period will be discontinued from the study (prior to 
randomization). 
 
IMPORTANT: Visit 2 and Visit 3 can be skipped, i.e., a participant can move 
directly from Visit 1 to Visit 4, if the following criteria are met at Visit 1: 
The participant is eligible based on the results of Visit 1 assessments, including 
laboratory values; 
Blood pressure is <140/90 mmHg; 
AND 
The participant meets one of the following criteria: 
Has been treated with a RASB for at least two months at a dose at least equivalent 
to Ramipril 10 mg or Irbesartan 300 mg;  
Has contraindications to RASB; 
Does not have evidence or history of micro- or macroalbuminuria (as defined in 
5.1.4) and is not being treated with RASB or other anti-hypertensive agents. 
If the above criteria are met and Visits 2 and 3 are skipped, Visit 4 will be 
scheduled 3 weeks after Visit 1 with a window of 2 weeks before and 3 weeks after 
the target date. The collection of medical history and the physical exam scheduled 
at Visit 2 will be conducted at Visit 4. 
 
Modification of visit schedule to 
reduce number of run-in study 
visits  and consequent duration 
of run-in period for participants 
who qualify 
p.29 8. STUDY PROCEDURES 
8.4. Enrollment in the Study 
and Randomization (Visit 5) 
Revised Text: 
 At the end of the run-in period, eligibility will be re-assessed based on the BP 
measures obtained at Visits 4 or 4A (if applicable), HLA-based genetic susceptibility 
to allopurinol skin reactions36,37 (tested at Visit 4), and a valid baseline iGFR 
measurement.  Participants who are eligible for randomization based on those 
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telephoned by the study coordinator to discuss how the study medication should be 
taken and its potential side effects. 
 
Deleted Text: 






P.30 8. STUDY PROCEDURES 
8.5. Treatment Period (Visits 
6 to 15) 
Revised Text: 
During the treatment period, the following procedures will be completed at each visit 
for each participant: 
Obtain interval medical history (with special emphasis on BP control and CVD 
events). 
Review of concomitant medications and AEs.   
Review RASB and BP therapy. 
Measure height, weight, and vital signs according to the schedule outlined in Figure 1 
Inspect for skin rash. (Visit 11) 
Conduct a physical exam (Visit 11). 
Perform ECG according to the schedule outlined in Figure 1 (Visit 11). 
Collect samples for clinical laboratory assessments and for storage of serum, plasma 
and urine for later biomarker research according to the schedule outlined in Figure 1. 
Perform pregnancy test in women of childbearing potential. 
Measure GFR by means of plasma disappearance of non-radioactive iohexol, iGFR at 
Visit 11.  
Provide a container and instructions for an overnight urine collection whenever an 
AER measurement is scheduled at the following visit. 




















P.30 8. STUDY PROCEDURES 
8.5. Treatment Period (Visits 
6 to 15) 
New Text: 
At some sites the study medication may be dispensed directly to the study 
participant at a relevant in person study visit or by mail from the site following a 
relevant in-person or phone study visit. 
 
Modification of study drug 
dispensing 




An Adverse Event (AE) is any untoward medical occurrence in a study participant 
regardless of its relationship to study treatment.  A treatment-emergent AE is an 
adverse event occurring during the period between the first dose and 30 days after the 
final dose of the study medication. A Serious Adverse Event (SAE) is any untoward 
medical occurrence that results in death, is life-threatening, requires hospitalization or 
prolongation of an existing hospitalization, results in persistent or significant disability, 
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or is a congenital anomaly/birth defect.  Important medical events that do not fall into 
the above categories may also be considered an SAE when, based on medical 
 safety and require medical/surgical 
intervention to prevent one of the outcomes listed in the SAE definition.  The term 
SAE is not intended as a measure of severity or intensity. 
after the time of informed consent will be reported. 
P.33 10. ADVERSE EVENT 
REPORTING 
10.2 Adverse Event 
Reporting 
Revised Text: 
All AEs will be reported on the Adverse Events form that will be completed by the 
study staff, who are masked as to study treatment assignment, at each regular follow-
up visits.  This will insure that AEs are ascertained in an unbiased manner using the 
same standardized methodology for participants in both treatment arms.  Forms will 
include standardized questions relating to specific events of import in diabetic patients 
on either of the study treatment arms as well as any significantly abnormal physical 
finding identified on examination and any significantly abnormal laboratory results 
obtained on the patient between visits or at the time of the visit.  AEs reported or 
ascertained between clinic visits will be captured and reported at the time of the next 
schedule visit.  Pre-existing conditions (that is, any conditions that was known to be 
present prior to  the signing of informed consent or was identified during the 
screening procedures at Visit 1) will not be considered or recorded as AEs unless the 
condition worsens in intensity or frequency after Visit 1.  Likewise, continuing AEs 
will not be reported as AEs at subsequent visits unless they increase in severity or 
frequency between visits, they results in criteria for a SAEs, and/or they resolve 
between visits.  Each site will be responsible for reporting all AE's to their IRB 
according to its AE reporting policy and procedures 
Clarifi  
p.46 14. DATA AND SAFETY 
MONITORING PLAN      
2. IRB Monitoring 
New Text: 
 Joslin Diabetes Center 
 University of Minnesota 
 University of Colorado 
 University of Michigan 
 Northwestern University 
 University of Toronto 
 Albert Einstein University 
 Washington University 
 Steno Diabetes Center 
 University of Calgary 
 Alberta Diabetes Institute 
 Emory University 
 University of Washington 
 
New clinical sites 
15 
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p.47 15. STUDY 
ADMINISTRATION             
15.1. Organization 
 
Revised Text:  
The Steering Committee is responsible for the design of the study and provides 
guidance to its execution.  Members are the co-Chairs of the PERL Consortium (Drs. 
Mauer and Doria), the Directors of the Clinical Sites (Drs. Caramori, Goldfine, Maahs, 
Perkins, Pop-Busui, Molitch, Crandall, Rossing, Sigal, Senior, Umpierrez and 
Hirsh), the Directors of the Data Coordinating Center (Drs. Galecki and Spino), and 
the Director of the Central Laboratory (Dr. Eckfeldt), the NIH program officers (Drs. 
Jones and Flessner), and the JDRF program officer (Dr. Nickerson). 
 
Revised Text: 
The Clinical Sites are located at the Joslin Diabetes Center, the University of 
Minnesota, the University of Colorado (Barbara Davis Center for Childhood Diabetes), 
the University of Michigan, Northwestern University, Albert Einstein College of 
Medicine, Washington University (St. Louis), the University of Toronto the Steno 
Diabetes Center (Denmark), the University of Calgary (Calgary, Alberta, Canada), 
Alberta Diabetes Institute (Edmonton, Alberta, Canada), Emory University and 
the University of Washington Medical Center (Seattle) are responsible for 
recruiting study participants and implementing the protocol. 
 










New clinical sites added 
List of Changes in PERL Protocol Version 9.0 August 16, 2016 
p.1 Title page  
 
Change version and date Version 9.0 Approved by the DSMB August 16, 2016            
 
Version date changed to date of 
DSMB approval 
p.2-4 Table of Contents  Page numbers 8-49 changed Page numbers shifted. 
p.5 Program Officers Revised Text: 
Marlon Pragnell, PhD 
Senior Scientist, Translational Development 
Juvenile Diabetes Research Foundation 
26 Broadway 
New York, NY 10004 
Phone: (212) 479-7690 





Scientific Program Manager: Complications 
Hnicjerson 
New Program Officer 
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p.6 Directors of Clinical Sites Revised Text: 
Sarit Polsky, MD, MPH 
Barbara Davis Center for Diabetes  
University of Colorado at Denver - Anschutz Medical Campus  
1775 Aurora Court, Mail Stop A140  
Aurora, CO 80045 P 
Phone: (303) 724-8575 




David Maahs PhD 
david.maahs@ucdenver.edu 
New Investigator 
p.6-7 Directors of Clinical Sites 
 
New Text: 
Ronnie Aronson, MD 
LMC Diabetes and Endocrinology 
1929 Bayview Avenue, Suite 107 
Toronto, ON Canada M4G 3E8 
Ph: (416) 646-2929 
Fax: (416) 645-2930 
Email: Ronnie.Aronson@LMC.CA 
Additional Investigator 
p.8 Directors of Clinical Sites 
 
New Text: 
Ildiko Lingvay, MD, MPH, MSCS 
University of Texas Southwestern Medical Center  
5323 Harry Hines Blvd., U9.134E  
Dallas, TX 75390-9302  
Phone: (214) 648-2779 
Fax: (214) 648-2885 
ildiko.lingvay@utsouthwestern.edu 
New Investigator 
p.8 Directors of Clinical Sites 
 
New Text: 
Katherine R. Tuttle, MD 
Providence Medical Research Center  
104 W. 5th Avenue, Suite 350E  
Spokane, WA 99204  
Phone: (509) 474-4345 





# Location Change Rationale 
p.8 Directors of Clinical Sites 
 
New Text: 
Tom Elliott MBBS, FRCPC 
BC Diabetes  
4102-2775 Laurel Street  
Vancouver, BC V5Z 1M9  
Phone: (604) 683-3734 ext. 1001  
Fax: (604) 628-3821 
telliott@bcdiabetes.ca 
New Investigator  
p.9 Central Laboratory Revised Text: 
Advanced Research and Diagnostics Laboratory 
Director:  Amy Karger, MD, PhD  
University of Minnesota  
Mayo Mail Code 609, Room Mayo D211  
420 Delaware Street, SE  
Minneapolis, MN 55455  
Ph: (612) 624-2150 






p.10 PROTOCOL SUMMARY 
Participating centers 
New Text: 
University of Washington (Seattle)  
University of Calgary (Calgary)  
University of Alberta (Edmonton)  
Emory University (Atlanta)  
Washington University (St. Louis)  
University of Texas Southwestern (Dallas)  
Providence Medical Research Center (Spokane)  
BC Diabetes (Vancouver).   
New sites added to enhance 
recruitment 
p.12 PROTOCOL SUMMARY 
Statistical methods 
Revised Text: 
The majority of data analyses, including the primary analysis, will be performed 
according to an intention-to-treat approach.   
Change in the analysis plan 
p.12 PROTOCOL SUMMARY 
Date of Protocol 
Revised Text: 
July 13, 2016 
Date approved by DSMB 
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p.15 1. INTRODUCTION 
 
Revised Text: 
It is very important to note that, in that study, the UA levels shortly after the onset of 
T1D was a significant independent predictor of macroalbuminuria 18 years later 
(hazard ratio 1.90 per mg/dl increase in UA level; p=0.04)11, this being suggestive of 
a pathogenetic role. 
Grammar clarification 
p.16 1. INTRODUCTION 
 
New text: 
To test this hypothesis, we have established a consortium of investigators from 
academic centers where large rosters of T1D patients are available along with long-
standing expertise in the study of diabetic complications, especially DN, and in DN 
clinical trials. Included in this initiative are the Joslin Diabetes Center, the Universities 
of Minnesota, Colorado, Toronto, Michigan, Washington (Seattle), Texas 
Southwestern, Calgary, and Alberta Northwestern University, Washington 
University (St. Louis), Emory University, Albert Einstein College of Medicine, BC 
Diabetes, Providence Medical Research Center, and the Steno Diabetes Center in 
Copenhagen, Denmark. The Consortium, led by Dr. Alessandro Doria from the Joslin 
Kidney Study, and by Dr. Michael Mauer, who recently led the Renin Angiotensin 
System Study (RASS) clinical trial, has been named PERL (Preventing Early Renal 
tervening early 
in the course of kidney disease, when renal damage is most likely to be able to be 
arrested or reversed and interventions are more likely to be effective. 
Addition of new centers 
p.16-17 4. PARTICIPATING 
CENTERS 
Revised /New Text:                                                                                        
The study will involve 16 centers that are part of the PERL Consortium: 
Joslin Diabetes Center (Boston) 
University of Minnesota (Minneapolis) 
University of Colorado (Barbara Davis Center for Childhood Diabetes, 
Denver) 
University of Michigan (Ann Arbor) 
University of Toronto (Toronto) 
Northwestern University (Chicago) 
Albert Einstein College of Medicine (New York) 
Steno Diabetes Center (Copenhagen, Denmark) 
Washington University (St. Louis, MO)  
University of Calgary (Calgary, Alberta, Canada) 
University of Alberta (Edmonton, Alberta, Canada) 
Emory University (Atlanta) 
University of Washington (Seattle) 
University of Texas Soutwestern (Dallas) 
Providence Medical Research Center (Spokane) 
This section has been revised to 
update the number of sites, add 
new sites and clarification of the 





# Location Change Rationale 
BC Diabetes (Vancouver) 
  
p.18 4. PARTICIPATING 
CENTERS 
4.1 Location of Study Visits 
New Text: 
 Blood samples for local lab tests (serum creatinine, K, and ALT, CBC, 
pregnancy tests) will be processed and analyzed at the facilities where samples are 
collected or shipped to commercial laboratories or to the Central Laboratory for 
testing. Results will be transmitted to the Study Site by fax or other secure methods. 
Reflects the ability of the Central 
Laboratory to analyze remote local 
lab specimens, in the event a lab in 
th
be identified. 
p.21 5. SUBJECT SELECTION 
5.5.1 Reasons for 
discontinuation 
Revised Text: 
The study drug will be temporarily discontinued if a participant: 
Has clinically significant persistent changes from baseline based on laboratory 
safety assessment results (the response to discontinuation will be monitored to assess 
whether the drug can be re-instituted, see next paragraph on permanent 
discontinuations).  
Requires treatment with allopurinol or medications that make allopurinol 
contraindicated (see 5.5.2 and 9.5). 
Becomes pregnant or breastfeeding (see 5.5.2)   
Whenever the reason for temporary discontinuation of the study drug ceases to 
exist, the study medication will be resumed with the consensus of the drug 
monitoring committee, according to the following procedures: 
If the study medication was discontinued because of a suspected drug reaction or 
the participant was off-medication for 3 months or longer, the study drug will be 
re-started at a dosage of 100 mg for 4 weeks, which will then be increased to the 
full dosage appropriate for the eGFR. (see 6.1.2)  
If the study medication was not discontinued because of a drug reaction and the 
participant was off-medication for less than 3 months, the study medication will 
be re-started, at the full dosage appropriate for the eGFR.  
The study drug will be permanently discontinued if a participant: 
Experiences an SAE related to the study drug or an intolerable AE such as a 
persistent allergy or rash. 
Has clinically significant persistent changes from baseline based on laboratory 
safety assessment results which do not respond to temporary 2-week discontinuation of 
study drug and re-institution of drug at ½ of the initial dose. 
Develops end- 73 m2, institution of 
chronic dialysis treatment or kidney transplantation) or iGFR decreases by 50% from 
one measurement to the next or serum creatinine levels double over any 12-month 
interval in the post-randomization period.  If these renal function changes prove to 
be temporary, the study medication could be resumed as described above with the 
consensus of the drug monitoring committee. 
Further clarify the resuming of 
study drug after discontinuation 
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p.23 6. STUDY TREATMENTS 
6.1.2. Dosage 
Revised Text: 
All participants, whether they are randomized to allopurinol or placebo, will be given 
four tablets per day to be taken orally following breakfast.  Tablets will be provided in 
four vials (A, B, C, and D) or in blister packs, in which each blister contains the 
four tablets for a given day. If the medication is provided in bottles, participants 
randomized to allopurinol will receive a dosage of 100 mg as a 100 mg tablet (from 
vial A) plus three placebo tablets (from vials B, C, D), 200 mg as two 100 mg (from 
vials A and C) and two placebo tablets (from vials B and D), 300 mg as three 100 mg 
(from vials A, B, C) and one placebo tablet (from vial D), 400 mg as four 100 mg 
tablets (from vials A, B, C, D). Subjects randomized to placebo will be given four 
placebo tablets (from vials A, B, C, D). If the medication is provided in blister 
packs, each blister will contain the four tablets for a given day, with the same 
proportion of active and placebo tablets described above for each allopurinol 
dosage and for placebo. 
The dose adjustment will be carried out as follows: 
At each follow-up visit, a study drug requisition will be sent by the clinical site 
to the research pharmacy indicating the study ID, name, and address of the participant, 
the most recent eGFR value (CKD-EPI), calculated using a recent local lab creatinine 
value, and the number of days to be covered by the drug supply.  
At the pharmacy, a clinical pharmacist will determine the allopurinol dose 
(ranging from 0 to 400 mg) that should be given at that time according to the study 
(CKD-EPI) calculated using a recent local lab serum creatinine value. 
The research pharmacy will mail the new batch of study medication directly to 
the study participant.  
At some sites the study medication may be dispensed directly to the study 
participant at a relevant in person study visit or by mail from the site following a 
relevant in-person or phone study visit. 
Participants will be instructed to immediately inform the clinical site upon 
receipt of the new tablets and mail the pill bottles or blister packs with the tablets 
remaining from the previous prescription in a provided pre-addressed mailer, to the 
clinical site for drug accounting and compliance assessment. 
Addition of ability to provide 
study medication in blister packs 
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p.23-24 6. STUDY TREATMENTS 
6.1.3. Compliance and 
Accountability 
Revised Text: 
Skills will be taught and reinforced at each visit with regard to scheduling and 
administration of pills at home and while traveling.  Methods (e.g. record-keeping) will 
be taught to help participants monitor tablet usage and enhance compliance. To 
complement the regular compliance interventions at the scheduled visits, study 
information and motivational materials (postcards, newsletters, etc.) will be mailed. In 
addition, at midpoint between clinic visits, participants will be phoned by the clinic 
staff to review pill-taking. Patients will be provided with random but known numbers 
of excess medications, providing extras in case of pill loss. Adherence will be 
monitored by instructing participants to expect extra pills and to mail the pill bottles or 
the blister packs with the tablets remaining from the previous prescription to the study 
center upon receipt of a new batch of tablets. The number of extra pills included in 
each supply of medications will be decided by the pharmacist, who will keep a record 
of it and will transmit this information to the Study Site.  Personnel at the Study Site 
will enter this information in the appropriate electronic Case Report Form along with 
the expected number of pills used during the period covered by the supply and the 
number of unused pills returned by the participant.  These data will be used to analyze 
compliance. If poor adherence is noticed, measures will be taken to increase 
compliance, such as explaining the purpose of the study again, providing pill 
reminders, and more frequently contacting the study subject by phone. Participants at 
each visit will be asked about their perceived compliance and about any difficulties 
with taking the study medications, but the individualized strategies to improve 
compliance will not be openly linked to the pill counts, i.e. participants will not be 
informed of the results of pill counting. Participants showing poor compliance will not 
be withdrawn from the study. 
Addition of ability to provide 
study medication in blister packs 
p.26 8. STUDY PROCEDURES 
8.1. Schedule of Events 
New Text: 
Outcome variables (plasma iohexol, serum creatinine and cystatin C, urinary AER), 
HbA1c, and serum uric acid will be measured by the Central Laboratory at the 




Adding new central lab director 
p.29 8. STUDY PROCEDURES 
8.1. Schedule of Events 
Revised Text: 
Note:  (x) indicates an optional assessment; 
indicates an optional assessment only if the patient is NOT seen in-person. 
Clarification as to when the BP 
measurement is truly optional 
P.31 8. STUDY PROCEDURES 
8.5. Treatment Period (Visits 
6 to 15) 
Revised Text: 
In the days immediately after each visit, upon completion of serum creatinine 
measurements, participants will receive a new batch of study medication by mail from 
the research pharmacy.  Upon receipt of the new tablets, participants will be instructed 
Addition of ability to provide 





# Location Change Rationale 
to immediately mail the pill bottles or the blister packs with the tablets remaining 
from the previous prescription to the study center for drug accounting and compliance 
assessment (see 6.1.2). A pre-stamped and addressed envelope will be provided to 
participants for this purpose. 
 
 
P.32 8. STUDY PROCEDURES 
8.6. End of Intervention 
(Visit 16) 
New Text: 
Participants will be instructed to stop taking the study medication and to mail the pill 
bottles or the blister packs with the tablets remaining from the last prescription to the 
study center if they did not already bring the unused study medication at the visit.  The 
RAS and BP therapy will be continued as before until the closing visit (Visit 17). The 
importance of coming back in 8 weeks for the closing visit (Visit 17) will be 
emphasized. 
 
Addition of ability to provide 
study medication in blister packs 






After collecting a detailed medical history at Visit 1, this information will be updated 
at each visit through a structured interview, with a special emphasis on skin symptoms 
and signs such as rash, itching and exfoliation and on pregnancy in females. 
Participants will be instructed to communicate any change in their health status and 
intervening hospitalizations to the study coordinator in-between visits.  In particular, 
they will be instructed to discontinue study medication and immediately contact the 
study coordinator if they develop a suspicious skin rash, swelling of the lips or mouth, 
arthralgias, and/or jaundice, which may indicate a hypersensitivity reaction to 
allopurinol.  Fever and chills should also be reported but would not require cessation of 
medication prior to discussion with study personnel. 
 
Deleted Text: 
Of any kind 
Clarification of skin rash 
triggering discontinuation of study 
drug 




This section presents a summary of the planned statistical analyses. A statistical 
analysis plan (SAP) will be written for the study that contains detailed 
descriptions of the analyses to be performed. The SAP will be written prior to 
database lock. 
Clarification of statistical analysis 
p.35 11. STATISTICAL 
ANALYSIS 
11.1. Analysis Population 
New Text: 
For most of the analyses, including the primary efficacy analysis described in 
section 11.3, an intention to treat (ITT) analytical approach will be employed.  
Accordingly, the population for statistical analysis will consist of all randomized study 
participants considered in their original randomization group, regardless of treatment 
discontinuation or loss to follow-up. 
Selected secondary efficacy analyses will be performed using a per-protocol 
Revised analysis plan 
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analytical approach. In this case, the analysis population will consist of the ITT 
population excluding data points which 1. had cumulative exposure to the study 
medication from randomization that was less than 80% of the theoretical full 
exposure; or 2. during major protocol deviations (e.g., treatment with prohibited 
medications), which could affect primary outcome. 
 
p.35 11. STATISTICAL 
ANALYSIS                        
11.3. Primary Efficacy 
Analysis 
 
New Text:  
For the primary endpoint (iGFR at the end of the 2-month wash-out period following 
the 3-year intervention), we will follow the recommendations by Carpenter et al38,39 
and perform the analysis by means of a linear model for correlated errors with 
general/unstructured covariance matrix using all available iGFR measures (including 
those at baseline, 80, 156, and 164 weeks, respectively) as the dependent variable. By 
conditioning on the baseline iGFR measure we will also effectively use this variable as 
a covariate. Treatment group, study center, stratifying variables, albuminuria status 
(subjects who qualified by ACR or AER or were albuminuric at baseline vs. 
subjects who did qualified by eGFR slope and were normoalbuminuric at 
baseline), baseline AER, time, and time by treatment interaction will also be included 
as covariates in the model. Three features make this analytical approach especially 
attractive:  
Revised analysis plan 
p.37 11. STATISTICAL 
ANALYSIS 
11.4. Secondary Efficacy 
Analyses 
New Text: 
We will perform a per-protocol analysis (as defined in 11.1) for the primary 
efficacy endpoint (iGFR at the end of the 2-month wash-out period following the 
3-year intervention). 
Revised analysis plan 
p.37-38 11. STATISTICAL 
ANALYSIS 
11.7. Model assumptions 
and alternative analyses 
New Text: 
Model assumptions will be thoroughly checked for individual and systematic 
departures, using informal, e.g. inspection of residuals, and formal methods such as 
score test for extra parameter or methods based on likelihood displacement. If 
individual outliers are detected, their influence will be evaluated using influence 
diagnostics methods based on comparing estimates from models fitted to data with and 
without outlying values. Whenever we are not successful in fitting the parametric 
model (linear or non-linear), then non-parametric analyses and/or transformation of the 
variables involved in the analysis will be considered. To investigate the potential 
hemodynamic influence of allopurinol on treatment effect, in addition to the 
aforementioned analyses, we will consider models including the post-randomization 
measure of GFR at 4 months as an additional covariate.  To investigate the possible 
presence of heterogeneity in the response to allopurinol, subgroup analyses (based on 
the primary efficacy analysis described in section 11.3, with the inclusion of an 
interaction term of the treatment group by the subgroup variable) will be 
Revised analysis plan 
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>70 ml/min/1.73m2), AER at baseline and albuminuria 
status (subjects who qualified by ACR or AER or were albuminuric at baseline 
vs. subjects who did qualify by eGFR slope and were normoalbuminuric at 
baseline). To investigate possible influence of using selected covariates on the 
treatment effect estimate in the models considered in Section 11, we will perform 
appropriate sensitivity analyses. These additional analyses will be considered as 
strictly exploratory. 
p.45 13.  PROTECTION OF 
HUMAN SUBJECTS 
13.5. Procedures for 
protecting against and 
minimizing potential risks, 
b. specific 
New Text: 
Subjects taking drugs known to interact with allopurinol in causing bone marrow 
depression will be excluded from the study.  White blood cell counts will be done 
before the study drugs are prescribed, and quarterly thereafter. The study drug should 
be temporarily discontinued should evidence of bone marrow depression 
(WBC<3500/mm3) be present and confirmed. WBC should be repeated two weeks 
after study drug discontinuation.  If WBC recovers, consider re-challenging and 
repeating WBC two weeks after drug re-introduction. In addition, if WBC is 
confirmed to be <2500/mm3 and/or ANC is <1000/mm3, the event also needs to be 
reported as an AE.   The Drug Monitoring Committee will review each case and 
decide whether a referral to a hematologist is warranted and whether study treatment 
can be reinstated after blood values have returned to normal. If drugs potentially 
causing bone marrow depression in combination with allopurinol are begun after entry 
into the trial, observations for this side effect will be intensified or, if recommended by 




Additional details directing follow 
up and reporting of possible bone 
marrow depression 
p.45 13.  PROTECTION OF 
HUMAN SUBJECTS 
13.5. Procedures for 
protecting against and 
minimizing potential risks, 
b. specific 
New Text: 
Blood pressure will be measured quarterly with the goal of maintaining BP 
within 2 weeks and if still elevated additional antihypertensive non-RAS blockers will 
satisfactory BP control within 2 months would lead to a case review by the Drug 





Allows flexibility to discuss cases 
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p.47 14. DATA AND SAFETY 
MONITORING PLAN 
New Text: 
IRB monitoring will be in place from: 
Joslin Diabetes Center 
University of Minnesota 
University of Colorado 
University of Michigan 
Northwestern University 
University of Toronto 
Albert Einstein University 
Washington University 
Steno Diabetes Center 
University of Calgary 
University of Alberta 
Emory University 
University of Washington 
University of Texas Southwestern 




Alberta Diabetes Institute 
 
Addition of new centers, and 
clarifying the name of an existing 





14. DATA AND SAFETY 
MONITORING PLAN 
Revised Text: 
A Drug Monitoring Committee (DMC) consisting of the PERL Center 
Directors and PIs, a research pharmacist, and the Project Manager will discuss any 
serious medication related problem that a participant has.  Changes in study medication 
dose, medication discontinuation and medication re-institution will be included in 
these discussions.  
 
Deleted text: 
hold conference calls  
discussed during these calls 
 
Allows flexibility to discuss cases 
via e-mail or means other than a 
call 




The Steering Committee is responsible for the design of the study and provides 
guidance to its execution.  Members are the co-Chairs of the PERL Consortium (Drs. 
Mauer and Doria), the Directors of the Clinical Sites (Drs. Caramori, Goldfine, Maahs, 
Perkins, Pop-Busui, Molitch, Crandall, Rossing, Sigal, Senior, Umpierrez, Hirsch, 
Adding new site directors, a 
change in central lab director, and 
correction to a name spelling error 
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Lingvay, Tuttle, Aronson and Elliott), the Directors of the Data Coordinating Center 
(Drs. Galecki and Spino), and the Director of the Central Laboratory (Dr. Karger), the 




Hirsh, Eckfeldt and Pragnell 




The Drug Monitoring Committee is responsible for the oversight of the 
study drug administration as well as the RAS blocking and antihypertensive therapy 
during the trial. Members are Dr. Doria, Dr. Mauer, the PIs of the clinical sites, the 
Project Manager, the Lead Clinical Coordinator, and a research pharmacist. The 





Correcting current number of sites 




The Clinical Sites are located at the Joslin Diabetes Center, the University of 
Minnesota, the University of Colorado (Barbara Davis Center for Childhood Diabetes), 
the University of Michigan, Northwestern University, Albert Einstein College of 
Medicine, Washington University (St. Louis), the University of Toronto, the Steno 
Diabetes Center (Denmark), the University of Calgary (Calgary, Alberta, Canada), 
University of Alberta (Edmonton, Alberta, Canada), Emory University, the University 
of Washington (Seattle), University of Texas Southwestern, Providence Medical 
Research, and BC Diabetes are responsible for recruiting study participants and 
implementing the protocol. 
Addition of new centers, and 
clarifying the name of an existing 
center for consistency 




The Central Laboratory, located at the University of Minnesota, is directed by Dr. 




Adding new central laboratory 
director 
List of Changes in PERL Protocol Version 10.0 March 6, 2018 
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Afshin Parsa, MD, MPH 
Program Director, Clinical Kidney Genomics, PKD and CKD NIDDK/NIH 
6707 Democracy Blvd. Room 6139 
Bethesda, MD 20892-5460 
Tel: (301) 827-1375 
New Program Officer 
  afshin.parsa@nih.gov  
  Deleted Text: 
Michael Flessner, MD, PhD 
Division of Kidney, Urologic, & Hematologic Diseases NIDDK, National Institutes of Health 
Building 2DEM, Room 641 6707 Democracy Blvd. 
Bethesda, MD 20817 





Directors of Clinical Sites 
Added Text: 
S. Michael Mauer, MD University of Minnesota 2450 Riverside Ave. East Building, MB681 
Minneapolis, MN 55454 
Mobile: (612) 703-5884 
Added mobile phone number 
p.6-7 GENERAL 
INFORMATION 
Directors of Clinical Sites 
New Text: 
Sylvia Rosas, MD 
Joslin Diabetes Center and Harvard Medical School One Joslin Place 
Boston, MA 02215 
Phone: (617) 309-2477 
Fax: (617) 309-3403 
Sylvia.Rosas@joslin.harvard.edu 
Deleted Text: 
Allison Goldfine, MD 
Joslin Diabetes Center and Harvard Medical School One Joslin Place 
Boston, MA 02215 
Phone: (617) 309-2643 
Fax: (617) 309-3403 
allison.goldfine@joslin.harvard.edu 
Change in Director of Clinical Site 
p. 8 GENERAL 
INFORMATION 
Directors of Clinical Sites 
New Text: 
Ian de Boer, MD, MS 
University of Washington Medical Center Box 359606 
325 9th Avenue, Room 3NJ357 Seattle, WA 98104 
New Director of clinical Site 
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Phone: (206) 616-5403 
Fax: (206) 685-9399IDeBoer@Nephrology.washington.edu 
Deleted Text: 
Irl B. Hirsch, MD 
University of Washington Medical Center  Roosevelt 4245 Roosevelt Way, NE, 3rd floor 
Box 354691 
Seattle, WA 98105 
Phone: (206) 598-4884 
Fax: (202) 598-4976 
ihirsch@uw.edu 
p. 12 Protocol Summary Revised Text: 
February 22, 2018 
 
p. 21 Discontinuation of study 
drug 
Reasons for Discontinuation 
New Text: 
Develops end-
of acute kidney injury [AKI], institution of chronic dialysis treatment or kidney 
transplantation) or iGFR decreases by 50% from one measurement to the next or serum 
creatinine levels double over any 12 month interval in the post-randomization period. 
If any of these renal function changes prove to be temporary, the study medication 





dialysis treatment or kidney transplantation) or iGFR decreases by 50% from one 
measurement to the next or serum creatinine levels double over any 12-month interval 
in the post-randomization period. If these renal function changes prove to be 
temporary, the study medication could be resumed as described above with the 
consensus of the drug monitoring 
Committee. 
Clarification of wording for 
developing ESRD and drug 
discontinuation. 
p. 22 Discontinuation of study 
drug Handling of study drug 
discontinuation 
New/Revised Text: 
Unless a participant withdraws consent all participants that are permanently 
discontinued from study drug or who discontinue study medication on their own will 
be followed for the full study period (i.e., 164 weeks, including the washout period) 
and all data will be collected as scheduled. 
 
Deleted Text: 
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p. 22 Discontinuation of study 
drug Handling of study drug 
discontinuation 
New Text: 
If a participant reaches ESRD as defined above under 5.5.1, he/she will be permanently 
discontinued from the study and invited to participate in a study close-out call or visit 
to be held within three months from the occurrence of ESRD. Data collection at this 
call or visit will be limited to standard adverse event reporting. In addition, sites should 
continue to contact participants who have reached end-stage renal disease to determine 
their final status until 3 years and 2 months after randomization. Major attempts will be 
made to schedule an end-of-study assessment for all participants who are lost to 
follow-up during the course of the study. 
New text was added to clarify 
handling of study drug 
discontinuation and data collection 
for specific scenario in which 
participant reaches ESRD. 
p. 35 Statistical Analysis 
Analysis Population 
Revised Text: 
Selected secondary efficacy analyses will be performed using a per-protocol analytical 
approach. In this case, the analysis population will consist of the ITT population 
excluding data points which 1. Had cumulative exposure to the study medication from 
randomization that was less than 80% of the theoretical full exposure; or 2. during 
major protocol deviations (e.g., treatment with prohibited medications), which could 
affect primary outcome. 
 
Deleted Text: 
all iGFR measurements/ did incur 
Grammar clarification. 
p. 49 Study Administration Revised Text: 
The Steering Committee is responsible for the design of the study and provides 
guidance to its execution. Members are the co-Chairs of the PERL Consortium (Drs. 
Mauer and Doria), the Directors of the Clinical Sites (Drs. Caramori, Rosas, Polsky, 
Perkins, Pop-Busui, Molitch, Crandall, Rossing, Sigal, Senior, Umpierrez, De Boer, 
Lingvay, Tuttle, Aronson and Elliott), the Directors of the Data Coordinating Center 
(Drs. Galecki and Spino), and the Director of the Central Laboratory (Dr. Karger), the 
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1. Overview  
 
DESIGN:  
 Multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial. 
 N=530 total number of subjects  
 
STUDY POPULATION: 
 Type 1 Diabetes  
 Inclusion/Exclusion Criteria listed in the Study Protocol   
 
STUDY TREATMENTS: 
 Oral allopurinol or placebo administered for 3 years followed by a 2-month washout 
 
PRIMARY OUTCOME MEASURE: 
 iGFR at the end of the 2-month wash-out period following the 3-year intervention 
 
STATISTICAL ANALYSIS PLAN: 
 This plan will be finalized prior to the database lock and unblinding of treatment groups
 
2. Schema  
 
Figure 2.1. PERL Study Schema 
 
 
3. Rationale for Adjustments of Statistical Analysis Plan as 
Compared to Protocol (Version 9, approved by DSMB on August 
16th, 2016)  
Changes from the protocol-specified definitions of aims, outcomes, and statistical analytical 
approaches are outlined below.  These changes reflect internal discussions since the design of the 
study that have not been incorporated yet as protocol amendments, but were discussed during the 
preparation of the Statistical Analysis Plan.  These changes and the rationale for their 
implementation are documented herein and represent changes made prior to the database lock 
and unblinding of the study. 
 
3.1. Use of modified Intention-to-Treat (ITT) Analysis Population 
RATIONALE: 
Given that some of the randomized subjects did not receive any study medication, data 




We define the ITT analysis population as  study participants considered in 




We define the mITT analysis population as all randomized study participants considered 
in their original randomization group, regardless of treatment discontinuation or loss to 
follow-up who received at least one dose of study medication.  
 
3.2. Simplified model for the primary efficacy analysis 
RATIONALE: 
The primary efficacy analysis presented in Section 11.2 of the study protocol was based on a 
linear model for correlated errors using all available iGFR measures (including those at 
baseline, 80, 156, and 164 weeks, respectively) as the dependent variable. The iGFR at 
baseline was included among the dependent variables to effectively adjust the treatment effect 
for baseline iGFR in the presence of a considerable number of missing values. Since iGFR 
values at baseline are missing for only two randomized subjects, which can be imputed in the 
analyses, we have decided to adjust for baseline iGFR in a standard way by including it as a 
covariate. Please note that both modeling approaches/specifications are equivalent if there are 
no missing iGFR values at baseline.  
 
PROTOCOL:   
correlated errors with general/unstructured covariance matrix using all available iGFR 
measures (including those at baseline, 80, 156, and 164 weeks, respectively) as the dependent 
variable. By conditioning on the baseline iGFR measure we will also effectively use this 
variable as a covariate. Treatment group, study center, stratifying variables, albuminuria status 
(subjects who qualified by ACR or AER or were albuminuric at baseline vs. subjects who did 
 
qualified by eGFR slope and were normoalbuminuric at baseline), baseline AER, time, and 
 
 
SAP:   
correlated errors with general/unstructured covariance matrix using all available post-
randomization iGFR measures (including 80, 156, and 164 weeks, respectively) as the 
dependent variable.  At any given visit, iGFR in this model depends on treatment group, study 
center, stratifying variables, iGFR at baseline, albuminuria status (subjects who qualified by 
ACR or AER or were albuminuric at baseline vs. subjects who did qualified by eGFR slope 
and were n  
 
4. Study Aim  
 
The study aim is to determine whether lowering serum UA by means of oral allopurinol is 
effective in preventing or slowing decline of renal function in T1D patients with history and/or 
presence of microalbuminuria or moderate macroalbuminuria, or with ongoing GFR loss 
regardless of history or presence of albuminuria, who have only mildly or moderately impaired 
kidney function. 
 
5. Study Endpoints and Other Outcomes 
This section describes the primary and secondary efficacy outcomes, as well as safety and other 
outcomes, that will be included in the primary manuscript.  Derivation of the endpoints and other 
outcomes from the data collected in the Case Report Forms will be described in detail in the 
Derived Dataset Requirements document. 
 
5.1. Primary Endpoint 
The primary endpoint is iohexol-plasma disappearance GFR (iGFR) at the end of the 2-month 
wash-out period (Visit 17 at Week 164) following the 3-year intervention. The rationale of 
measuring the primary outcome at the end of the wash-out period is to test allopurinol for 
permanent effects on the natural history of kidney disease, independent from any transient, 
hemodynamic effect that the medication may have on GFR.   iGFR is calculated from blood 
samples drawn at baseline and 120, 150, 180, 210, and 240 minutes after an i.v. bolus of 
iohexol, adjusting for body surface area. If there are fewer than five measures or the other 
quality criteria described in the protocol are not met, the iGFR value is not used in the 
analysis. 
 
5.2. Secondary Outcome Measures 
 
5.2.1. Secondary endpoint: iGFR at the end of the 3-year treatment period (Visit 16, 
before the washout) 
iGFR calculated at the end of the 3-year intervention (at Visit 16, last visit before washout) 
as measured by the plasma disappearance of non-radioactive iohexol. 
 
5.2.2. Secondary endpoint: iGFR time trajectory estimated from repeated iGFR 
measurements 
Repeated measures of iGFR at Visits 11, 16, 17. 
 
5.2.3. Secondary endpoint: Estimated (eGFR) at 4 months after randomization (Visit 
7)    
eGFR at 4 months after randomization as estimated from serum creatinine and cystatin C 
using the CKD-EPI SCr and the CKD-EPI SCr-SCysC equations  (Fan et al, 2015). This 
endpoint is employed to measure a transient, hemodynamic effect that the study medication 
may have on GFR. 
 
5.2.4. Secondary endpoint: Estimated GFR (eGFR) time trajectory  
Repeated eGFR measures at all post-randomization visits (Visit 6 through 17) as estimated 
from repeated serum creatinine and cystatin C measurements using the CKD-EPI SCr and 
the CKD-EPI SCr-SCysC equations.   
 




This secondary endpoint is defined as a composite of two events: (1) ESRD, defined as 
2, institution of chronic dialysis treatment or kidney 
transplantation, or (2) Doubling of serum creatinine levels as compared to baseline levels. 
Time to doubling of serum creatinine or ESRD is defined as the time from randomization 
to the first event (doubling of serum creatinine or ESRD) or censoring (lost-to-follow-up, 
withdrawal, and study completion without experiencing the event). 
 
5.2.6. Secondary endpoint: Urinary AER at the end of the two-month wash-out period 
(Visit 17) 
Geometric mean of two urinary AER measures obtained at Visit 17. 
  
5.2.7. Secondary endpoint: Urinary AER during the last three months of the 
treatment period (Visits 15 and 16) 
Geometric mean of urinary AER measures at Visit 15 and Visit 16.  
 
5.2.8. Secondary endpoint: Time to fatal or non-fatal cardiovascular events 
This secondary endpoint is defined as a composite of multiple events: (1) Cardiovascular 
disease (CVD) death (ICD-10 code I10 to I74.9), (2) Myocardial infarction, (3) Stroke 
(ischemic or hemorrhagic), (4) Coronary artery bypass grafting, or (5) Percutaneous 
coronary intervention. Time to fatal or non-fatal cardiovascular events is defined as the 
time from randomization to the first event (one of the events defined above) or censoring 
(lost-to-follow-up, withdrawal, non-CVD death, and study completion without 
experiencing the event). 
 
5.3. Safety measures 
Safety measures are assessed during three periods of the study:  run-in (Visits 1-5), treatment 
(after Visit 5 through Visit 16), and off-treatment washout (after Visit 16 through Visit 17).  
Safety will be summarized overall (treatment and off-treatment combined) and by period, 
depending on the safety outcome of interest during that period.  
 Percentage of subjects with SAEs, number of SAEs, time to first SAEs during on-
treatment period.  
 Percentage of subjects with and number of permanent discontinuations of study 
medication because of adverse effects. 
 Percentage of subjects with and number of AEs, overall and by severity and by 
relatedness to study medication. 
 Percentage of subjects with skin rash during on-treatment period. 
 
5.4. Other measures 
In addition to primary, secondary, and safety measures, the following additional outcomes 
will be analyzed to help with the interpretation of study results.  
 
 Body weight, blood pressure, serum creatinine, HbA1c, and serum uric acid at each 
post-baseline visit and their changes from baseline 
 Percentage of subjects receiving adequate study medication exposure (i.e., allopurinol 
or placebo) independent of adverse events. This is defined as the actual total dose 
during the 156-week dosing period, as determined from the dispensed dosage and pill 
counts, divided by the expected total dose defined by the eGFR-adjusted protocol-
described dosing regimen, without consideration for temporary or permanent 
discontinuations or reductions owing to adverse events.  The proportion of subjects 
receiving the adequate intended study medication exposure is defined as the number of 
subjects who had at least 80% and no more than 120% of the intended study 
medications during the entire dosing period, independent of adverse events, among all 
randomized subjects. 
 
6. Analytical Strategy 
In the initial analysis of the primary outcome we will present iGFR univariate statistics by 
Treatment Groups at each study visits (V4, V11, V16 and V17). 
 
level to be used at the final analysis will be 0.05 for the primary endpoint.  All other secondary 
outcomes will also be tested at the 5% level, with no adjustment for multiplicity.  Many of the 
models used in efficacy analyses include baseline covariates, such as stratifying variables (serum 
uric acid (sUA), HbA1C, clinical site), iGFR, albuminuria status (subjects who qualified by ACR 
or AER or were albuminuric at baseline vs. subjects who qualified by eGFR slope and were 
normoalbuminuric at baseline), AER, and time, and time by treatment interaction.  If there are 
problems with fitting these models, due, for example, to lack of convergence to optimal values, 
covariates will be eliminated from the models in the following order: baseline AER, albuminuria 
status, clinical site, serum uric acid (sUA), and HbA1c. More detailed information about these 
covariates is included in Section 6.4.  
 
6.1. Study populations 
Two study populations will be defined for the purpose of data analysis: 
 Modified Intention to Treat (mITT):  The mITT analysis set consists of all subjects 
enrolled in PERL, randomized to study medication, and receiving at least one dose of 
study medication. 
 Per Protocol:  The per protocol analysis set will consist of a subset of mITT subjects.   
The per protocol population will exclude subjects with major protocol deviations  
(defined as receiving the wrong study medication) as well as data points for which the 
cumulative exposure to the study medication from randomization to that time point 
was less than 80% of the theoretical full exposure (see Section 11.1 in the protocol). 
 
To account for missing values in any specific analysis, all subjects meeting the study 
population definitions will be included in the analysis using (1) appropriate analytical 
approaches that allow for missing values under plausible missing data mechanisms, or (2) 
analytical methods (defined within specific analyses) that allows the imputation of missing 
outcomes.  
 
Since the mITT approach can result in the need to analyze data with missing values of the 
outcomes (or covariates), we will follow four strategies proposed by I.R. White et al (2011): 
1. Attempt to follow up all randomized participants, even if they withdraw from 
allocated treatment. 
2. Perform a main analysis of all observed data that are valid under a plausible 
assumption about missing data. 
3. Perform sensitivity analyses to explore the effect of departures from the assumptions 
made in the main analysis. 





6.2. Blinded Data Review 
Prior to unmasking the study and starting any formal analysis, data will be reviewed in a 
blinded fashion by computing summary statistics for primary and secondary outcomes, and 
baseline covariates.  This will allow the identification of unusual values and/or patterns of 
missing values for key variables that need to be queried.   In addition, such blinded data 
review will allow the writing committee to assess the format of data presentation.  Note that 
the blinded data review incorporates real data but random treatment assignment (i.e., 
investigators do not receive data summarized by actual treatment group, rather they review 
data on two randomly formed groups). All decisions will be made and documented in this 
SAP document prior to database lock and unblinding. 
 
6.3. Visit Windows 
To provide scheduling flexibility to study sites and participants, visits were required to occur 
within a protocol-defined window rather than on a specific date. The protocol-defined visit 
windows are summarized in the table below.  For analytic purposes, the visit windows defined 
in the protocol will be expanded in order to eliminate gaps between them.  This will ensure 
that all observations, including those that may have occurred outside a protocol-specified time 
window, will be associated with the most appropriate visit and therefore properly included in 
the analysis.  If multiple observations occur within a window, the one closest to the visit target 
date will be utilized.  If two observations are equi-distant from the target date, the first one 
will be utilized.  
 




of Window (Week, 
Excluding First 
day) 
Per protocol Target Date 
window in weeks 
Upper Boundary of 
Window (Week, 
Including last day) 
Visit Windows Relative to Visit 5 Date 
Visit 6 0 4 [3-5] 10 
Visit 7  10  16 [14-20] 24 
Visit 8 24 32 [30-34] 40 
Visit 9 40 48 [46-50] 56 
Visit 10 56 64 [62-66] 72 
Visit 11 72 80 [78-84] 88 
Visit 12 88 96 [94-98] 104 
Visit 13 104 112 [110 -114] 120 
Visit 14 120 128 [126 -130] 135 




of Window (Week, 
Excluding First 
day) 
Per protocol Target Date 
window in weeks 
Upper Boundary of 
Window (Week, 
Including last day) 
Visit 16 149 156 [154 -160] 160 
Visit Window relative to V16 
Visit 17 0 8 [6 12] 16 
 
All intervals (target dates and lower/upper window boundaries) for visits 6 through 16 are 
calculated relative to the Visit 5 date. The interval for Visit 17 is calculated relative to Visit 
16.  Lower and upper boundaries are based on the mid-points between target dates. Most post-
randomization visits are 16 weeks apart, with the exception of Visits 6 and 7 and Visits 16 to 
visit 17. 
 
6.4. Covariates  
The following is a description of the covariates that will be used in the various analyses 
outlined in the remainder of Section 6.  
 Stratifying variables 
 serum uric acid (sUA) at baseline with 2 levels and > 6.0 mg/dl) 
 glycated hemoglobin (HbA1c) at baseline with two levels  
 clinical site/study center with 16 levels (based on main sites with satellite sites 
collapsed into main sites) 
 Baseline iGFR measured at Visit 4 
 Baseline eGFR measured at Visit 4 
 Treatment group with two levels (Allopurinol, Placebo) 
 Albuminuria status with 2 levels (subjects who qualified by ACR or AER or were 
albuminuric at baseline vs. subjects who qualified by eGFR slope and were 
normoalbuminuric at baseline) 
 Baseline AER geometric mean  (at Visits 3 and 4 combined) expressed on log to base 
10 scale 
 
At the time of writing, we have complete data available for serum uric acid, treatment group, 
and study center. The number of missing values for the other baseline covariates is 2 for 
iGFR, 6 for HbA1c, and 2 for albuminuria status. Given the small number of missing values 
for baseline covariates, we will employ single-value stochastic regression model imputation 
(Van Buuren, 2012). 
 
6.5. Analysis of the Primary Endpoint 
 
6.5.1. Primary Analysis of the Primary Endpoint 
The goal of the primary analysis will be to test the null hypothesis of the difference 
between treatment arms in the primary endpoint (iGFR at the end of the 2-month wash-out 
period [Visit 17] following the 3-year intervention) being equal to zero.  The analysis will 
be performed on the modified intention-to-treat (mITT) population and will employ a linear 
 
model for correlated errors with general/unstructured covariance matrix (Molenberghs and 
Verbeke, 2005; Galecki and Burzykowski, 2013). For each time t ( ) 
corresponding to post-randomization iGFR visits, i.e. visits V11 (80 weeks), V16 (156 
weeks), and V17 (164 weeks after randomization) the model equation is specified as: 
 
 
where  is the value of iGFR at time  for subject  ( ). Fixed effects 
 for  denote visit-specific intercepts and treatment effects.   is 
treatment group (equal to 1 for the allopurinol and 0 for placebo). Stratifying variables 
(serum uric acid, HbA1c, study center), and baseline covariates: albuminuria status, AER, 
iGFR for subject  are included in a vector  of  covariates  and associated 
fixed effects are stored in vector . We assume that residual errors   
( for subject  are normally distributed with zero mean and 3x3 
general/unstructured variance-covariance matrix. The model specified in (6.1) will yield 
the estimates of visit-specific treatment effects for all three visits V11, V16 
and V17. In the context of the primary analysis of the primary endpoint, we are interested 
in parameter , representing treatment effect at Visit 17 adjusted for stratifying variables 
and baseline covariates. 
 
Analysis Primary Analysis of the Primary Endpoint: iGFR at the end of the 2-month wash-
out period (Visit 17) 
Analysis Set mITT Population 
Methods Linear model for repeated measures with correlated errors 
Dependent 
Variable 
iGFR measured at Visits V11 (80 weeks) , V16 (156 weeks) and V17 (164 weeks 
after randomization) 
  
Model Fixed effects:  
 Visit-specific intercepts corresponding to V11, V16, V17 
 Visit-specific treatment effects corresponding to V11, V16, V17 
 Stratifying variables: sUA, HbA1c, study center  
 Albuminuria status with 2 levels  
 Baseline AER geometric mean  (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR  
Results  Predicted iGFR means at Visit 17 for an exemplary subject by treatment 
group.  
 Estimate of treatment effect at Visit 17 adjusted for baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
6.5.2. Secondary Analysis of the Primary Endpoint 
The primary analysis of the primary endpoint will be performed under the missing at 
random (MAR) assumption, i.e. the probability that the iGFR is missing depends on 
observed rather than unobserved values of the dependent variable. Although we consider 
the MAR assumption to be sensible for our study, the following sensitivity analyses will be 
performed to assess how alternative definitions of the primary endpoint (as defined above) 




1. Analysis of covariance using iGFR values at Visit 17 as the dependent variable and 
treatment effect as a covariate of primary interest. The same baseline covariates, as in 
the primary analysis of the primary endpoint, stored in vector  (see Equation. 6.1) 
will be used in the model. 
2. Performing an analysis identical to the primary one (same endpoint and model) using 
the per-protocol analysis set rather than the mITT analysis set.  
 
6.6. Analyses of Secondary Endpoints 
 
6.6.1. iGFR at the end of the 3-year treatment period (Visit 16, before the washout)  
The predicted means at Visit 16, estimate of treatment effect at Visit 16 adjusted for 
baseline covariates, their 95% confidence interval and P-value will be obtained as part of 
the primary analysis of the primary endpoint (Equation (6.1) in section 6.1.1). In the 
context of this secondary endpoint, we are interested in fixed effect , which represents 
treatment effect at Visit 16 adjusted for stratifying variables and baseline covariates. 
 
6.6.2. iGFR time trajectory estimated from repeated iGFR measurements 
 
Analysis Analysis of the Secondary Endpoint: iGFR time trajectory estimated from 
repeated iGFR measurements 
Analysis Set mITT Population 
Methods Linear mixed-effects model for longitudinal iGFR measures  
Dependent 
Variable 
iGFR measured at Visits V11 (80 weeks) , V16 (156 weeks) and V17 (164 weeks 
after randomization)  
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group 
 Time since randomization in days 
 Time by treatment group interaction  
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR 
 
Subject-specific random effects 
 Random intercept for iGFR 
 Random slope for iGFR  
Results  iGFR slope estimates and 95%CIs by treatment group  
 Estimate of a treatment effect measured as a difference between average 
slopes of iGFR versus time for allopurinol and placebo  groups adjusted 
for stratifying variables and baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
6.6.3. eGFR at 4 months after randomization (Visit 7) 
 
Analysis Analysis of the Secondary Endpoint: eGFR at 4 months after randomization 
(Visit 7) 
 
Analysis Set mITT Population 
Methods Linear model  
Dependent 
Variable 
eGFR measured at Visit V7 (16 weeks after randomization) 
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline eGFR 
Results  Predicted eGFR means at Visit 7 for an exemplary subject by treatment 
group.  
 Estimate of treatment effect at Visit 7 adjusted for stratifying variables 
and baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
6.6.4. eGFR time trajectory  
 
Analysis Analysis of the Secondary Endpoint: eGFR time trajectory estimated from 
repeated eGFR measurements 
Analysis Set mITT Population 
Methods Linear mixed-effects model for longitudinal eGFR measures  
Dependent 
Variable 
Post-randomization eGFR measured from  Visits V6 through V17 
  
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group 
 Time since randomization in days 
 Time by treatment group interaction  
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline eGFR 
 
Subject-specific random effects 
 Random intercept for eGFR 
 Random slope for eGFR  
Results  eGFR slope estimates and 95%CIs by treatment group  
 Estimate of a treatment effect measured as a difference between average 
eGFR versus time slopes for allopurinol and placebo  groups adjusted 
for stratifying variables and baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
6.6.5. Time to serum creatinine doubling or ESRD 
 
Analysis Analysis of the Secondary Endpoint: Time to composite endpoint of serum 
creatinine doubling or ESRD 
Analysis Set mITT Population  




Time to composite endpoint of serum creatinine doubling or ESRD 
Cox Model Fixed effects associated with:    
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR 
Results  N(%) of subjects with doubled serum creatinine or ESRD during the 
course of the study  
 Hazard ratio of allopurinol to placebo 
 95% confidence interval for hazard ratio 
 P-value for treatment effect 
  
6.6.6. Urinary AER at the end of the wash-out period 
 
Analysis Analysis of the Secondary Endpoint: AER at the end of the wash-out period  
Visit 17  
Analysis Set mITT Population 
Methods Linear model  
Dependent 
Variable 
Two AER measures obtained at Visit 17 and summarized using the geometric 
mean expressed on logarithm base to 10 scale 
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  Predicted urinary AERs at Visit 17 for an exemplary subject by 
treatment group 
 Estimate of treatment effect at Visit 17 expressed on percent change 
scale using antilog transformation. 
 95% confidence interval for treatment effect expressed on percent 
change scale using antilog transformation. 
 P-value for treatment effect 
 
 
6.6.7. Urinary AER during the last three months of the treatment period (Visits 15 
and 16) 
 
Analysis Analysis of the Secondary Endpoint: AER at the end of the treatment 
period (Visits V15 and V16) 
Analysis Set mITT Population 
Methods Linear model  
Dependent 
Variable 
Two AER measures obtained at Visit 15 and 16 are summarized using 
the geometric mean expressed on logarithmic scale 
Model Fixed effects associated with:  
 
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  Predicted AERs at the end of treatment period for an exemplary subject 
by treatment group.  
 Estimate of treatment effect at the end of treatment period adjusted for 
baseline covariates expressed on percent change scale using antilog 
transformation. 
 95% confidence interval for treatment effect expressed on percent 
change using antilog transformation. 
 P-value for treatment effect 
 
6.6.8. Time to fatal or non-fatal cardiovascular events 
 
Analysis Analysis of the Secondary Endpoint: Time to fatal or non-fatal cardiovascular 
events 
Analysis Set mITT Population  
Methods Cox proportional hazards model 
Dependent 
Variable 
Time to composite endpoint: fatal or non-fatal cardiovascular events 
Cox Model Fixed effects:   
 Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  N(%) of subjects with fatal or non-fatal cardiovascular events during the 
course of the study 
 Hazard ratio of allopurinol to placebo 
 95% confidence interval for hazard ratio 





6.7. Subgroup Analyses 
To investigate the possible presence of heterogeneity in the response to allopurinol, subgroup 
analyses (based on the primary efficacy analysis described in subsection 6.6.1, with the 
inclusion of appropriate interaction terms with the subgroup variable) will be performed by 
2), AER 
albuminuria status (subjects who qualified by ACR 
or AER or were albuminuric at baseline vs. subjects who did qualify by eGFR slope and were 
normoalbuminuric at baseline). 
 
 
An example of such subgroup analysis for age groups  
Similar to Equation (6.1) for each time t ( ), corresponding to visits V11, V16, V17, 
we specify the model: 
 
 
where  is the value of iGFR at time  for subject  ( ). Fixed effects 
 for  denote visit-specific intercepts, treatment effects, age effects 
and age by treatment interactions, respectively.   is treatment group (equal to 1 for the 
allopurinol and 0 for placebo).  tratifying 
variables, and baseline covariates albuminuria status, AER, iGFR for subject  are included in 
a vector of covariates  and associated fixed effects are stored in vector . We assume that 
residual errors   ( for subject  are normally distributed with zero mean and 3x3 
general/unstructured variance-covariance matrix. The model specified in (6.2) will yield the 
estimates of visit-specific treatment by age interaction effects for all three visits 
V11, V16 and V17. In the context of subgroup analysis, we are interested in , which 
represents treatment by age interaction at Visit 17 adjusted for baseline covariates. 
 
Analysis Subgroup Analysis of the Primary Endpoint: iGFR at the end of the 2-month 
wash-out period (Visit 17) by Age group 
Analysis Set mITT Population 
Methods Linear model for repeated measures with correlated errors 
Dependent 
Variable 
iGFR measured at Visits V11 (80 weeks) , V16 (156 weeks) and V17 (164 weeks 
after randomization) 
Model Fixed effects:  
 Visit-specific intercepts, age effects, treatment effects and age by 
treatment interaction effects 
 Stratifying variables: sUA, Hba1c, Study center 
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  Estimate of age by treatment interaction at Visit 17 adjusted for baseline 
covariates 
 95% confidence interval for age by treatment effect interaction at Visit 
17 
 P-value for treatment effect 
 
6.8. Analyses of Safety Outcomes 
For dichotomous safety outcomes, the proportion of subjects experiencing adverse outcomes 
exact tests.  Poisson regression models will be used for safety outcomes (e.g., SAEs and AEs) 
with multiple recurrences per patient, with logarithm of the period of observation from the 
time of study medication used as the offset. Time to first SAE will be analyzed using Kaplan-
Meier methods to estimate the SAE-free distributions for each treatment group.  This analysis 




6.9. Model assumptions and alternative analyses 
Model assumptions will be thoroughly checked for individual and systematic departures, 
using informal, e.g. inspection of residuals, and formal methods such as methods based on 
likelihood displacement. If individual outliers are detected, their influence will be evaluated 
using influence diagnostics methods based on comparing estimates from models fitted to data 
with and without outlying values. Whenever we are not successful in fitting the parametric 
model (linear or non-linear), then non-parametric analyses and/or transformation of the 
variables involved in the analysis will be considered. 
 
 
7. Table, Listing and Figure Shells  
 
Figure 7.1. Time from Randomization to End of Study by Treatment Group 
 
Kaplan-Meier plot of time from randomization to End of Study (death, withdrawal or lost-to-
follow-up) in months 
 
X axis label = Time (months) post-randomization (0, 6, 12, 18, 24, 36 months) 
 


















    
Assessed for eligibility (n = X) 
Allocated to Allopurinol 
 
 
Received allocated intervention (n 
 
 









Allocated to Placebo 
 
 
Received allocated intervention (n 
 
 
Did not receive allocated 
 
(give reasons) 
Excluded (n = X) 
 
Did not meet inclusion criteria (n = X) 
Withdrew (n = X) 
Lost to follow-up (n = X) 
Other reasons (n = X) 







Lost to follow up 
(n = ) (give reasons) 
(give reasons) 
Lost to follow up 
 
(give reasons) 
Run-In Period (n = X) 
Discontinued during the Run-in (n = X) 
 
Ineligible (n = X) 
Withdrew (n = X) 
Death (n=X) 
Lost to follow-up (n = X)  
Other reasons (n = X) 
 
Table 7.1. Patients disposition by Treatment Group. All Subjects 
 
 N (%) 
SCREENING PERIOD (at Visit 1) N 
Discontinuations after Visit 1 and before Visit 2 xx.x% 
       Screen Failure (Ineligible for Run-in) xx.x% 
       Withdrawal xx.x% 
       Lost to Follow-up xx.x% 
       Other xx.x% 
Eligible for Run-in xx.x% 
RUN-IN PERIOD  
(at Visit 2 through Visit 4) 
N 
Discontinued during Run-in (at Visit 2 through Visit 
4) 
N 
       Ineligible  xx.x% 
       Death  xx.x% 
       Lost to Follow-up xx.x% 
       Withdrawal xx.x% 
       Other xx.x% 
RANDOMIZED (Visit 5) xx.x% 





Randomized n n 
Post-Randomization Discontinuations n n 
       Death n n 
       Lost to Follow-up n n 
       Withdrew Consent n n 
       Other n n 
Post-Randomization Discontinuations /# Randomized 
(%) 
xx.x% xx.x% 
Completed Study n n 
Completed Study (%) xx.x% xx.x% 
 
 
Table 7.2. Patient Follow-Up by Treatment Group. All Subjects. 
 






Screened (Visit 1)   N 
Randomization   N/N_S (xx%) 
Visit 6 N_Visit 6/N* (xx%) N_Visit 6/N* (xx%) N_Visit 6/N* (xx%) 
Visit 7 N_ Visit 7/N* (xx%) N_ Visit 7/N* (xx%) N_ Visit 7/N* (xx%) 
Visit 8 N_ Visit 8/N* (xx%) N_ Visit 8/N* (xx%) N_ Visit 8/N* (xx%) 
Visit 9 N_ Visit 9/N* (xx%) N_ Visit 9/N* (xx%) N_ Visit 9/N* (xx%) 
Visit 10 N_ Visit 10/N* (xx%) N_ Visit 10/N* (xx%) N_ Visit 10/N* (xx%) 
Visit 11 N_ Visit 11/N* (xx%) N_ Visit 11/N* (xx%) N_ Visit 11/N* (xx%) 
Visit 12 N_Visit 12/N (xx%) N_Visit 12/N (xx%) N_Visit 12/N (xx%) 
Visit 13 N_ Visit 13/N* (xx%) N_ Visit 13/N* (xx%) N_ Visit 13/N* (xx%) 
Visit 14 N_ Visit 14/N* (xx%) N_ Visit 14/N* (xx%) N_ Visit 14/N* (xx%) 
Visit 15 N_ Visit 15/N* (xx%) N_ Visit 15/N* (xx%) N_ Visit 15/N* (xx%) 
Visit 16 N_ Visit 16/N* (xx%) N_ Visit 16/N* (xx%) N_ Visit 16/N* (xx%) 
Visit 17 N_ Visit 17/N* (xx%) N_ Visit 17/N* (xx%) N_ Visit 17/N* (xx%) 
    
Completed Across All Visits    
% Completed of Total   N_i /n =xx%  
Analysis Sets for Primary Endpoint:  
mITT Analysis Set1 N N n 
Per Protocol Analysis Set2 N N n 
1 modified intention to treat (mITT) analysis set will consist of all subjects enrolled in PERL, randomized to study medication 
who received at least one dose of study medication. 
 
2 per-protocol analysis set will consist of a subset of mITT subjects. The per-protocol analysis set will exclude data points which 
1. had cumulative exposure to the study medication from randomization less than 80% of the theoretical full exposure; or 2. with 
major protocol deviations (e.g., treatment with prohibited medications).  
 




Table 7.3. Demographics and Baseline Characteristics by Treatment Group. ITT Analysis 
Set. 
 






Age (years)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
BMI (kg/m2) (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
Diabetes duration (years)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
SBP (mm Hg)  (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
DBP (mm Hg) (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
BP (Visit 4), n (%)   
   SBP > 140 or DBP > 90 mm Hg   
 
   SBP 140 and DBP <=90 mm Hg   
   Missing   





Table 7.3. Demographics and Baseline Characteristics by Treatment Group. ITT Analysis 
Set. (continued) 
 






Gender, n (%)   
   Male   
   Female   
Ethnicity, n (%)   
   Hispanic or Latino   
   Not Hispanic or Latino   
   Unknown   
Race, n (%)   
   American Indian or Alaska Native   
   Asian   
   Black or African American   
   Native Hawaiian or Other Pacific Islander   
   White   
   Multi-Race   



















Table 7.4. Baseline Laboratory Values by Treatment Group. ITT Analysis Set. 
 






HbA1c (Visit 1) (%)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
HbA1C (Visit 1), n (%)   
      
   >7.8%   
   Missing   
Serum Uric Acid (mg/dL) (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
Serum Uric Acid (Visit 4), n (%)   
   6 mg/dL   
   > 6 mg/dL   
   Missing   
eGFR (ml/min/1.73 m2) (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
iGFR (ml/min/1.73 m2) (Visit 4)   
   Mean (SD)   
   Median (Q1, Q3) 
   Min, Max   
   N missing   
AER (ug/min) (Geometric mean for Visits 3 and 4)   
   Median (Q1, Q3) 
   Min, Max 
   N missing 
 
AER, n (%) (Geometric mean for Visits 3 and 4)   
   <20   ug/min   
   20-199 ug/min   
      









Table 7.4. Baseline Laboratory Values by Treatment Group. ITT Analysis Set. (continued) 
 






Potassium (mmol/L) (Visit 4)    
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
Hemoglobin (gm/dl) (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
Platelets (mmol) (Visit 4)   
   Mean (SD) 
   Median (Q1, Q3) 
   Min, Max 
   N missing 
White Blood Cell (cells/mcL) (Visit 4)   
   Mean (SD)   
   Median (Q1, Q3) 
   Min, Max   




7.1. Analyses of Primary and Secondary Outcomes 
 
P1. Primary Analysis of the Primary Endpoint: iGFR at the end of the 2-month wash-
out period (Visit 17). mITT Analysis Set1. 
 





iGFR Predicted Means at the end 
of the 2-month wash-out period 
(Visit 17) (95% CI)2 
x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect at Visit 17 
(95% CI) 
x.xx (x.xx, x.xx) 
p-value 0.xxxx 
1 Results are obtained from a linear model with correlated errors. The dependent variable is iGFR 
measured at visits V11, V16 and V17. Treatment effect at V17 was adjusted for stratifying variables 
(serum uric acid, HbA1c, study center), albuminuria status, baseline AER geometric mean (at Visits 3 
and 4 combined) expressed on log to base 10 scale, baseline iGFR.  
 
2Predicted means are calculated for an exemplary subject assuming that he/she is albuminuric from the 
Joslin site, with uric acid posited at 6 mg/dL, HbA1c at 8%, baseline AER geometric mean at 80 
g/min and baseline iGFR at 70 ml/min/1.73 m2. Covariate values for this exemplary subject were set 
close to their median values for continuous variables and most frequent categories for categorical 
variables 
 
S_1. iGFR at the end of the 3-year treatment period (Visit 16, before the washout). 
mITT Analysis Set.1 
 





iGFR Predicted Means at Visit 
16, before the wash-out period 
(95% CI)2 
x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect at Visit 16 
(95% CI) 
x.xx (x.xx, x.xx) 
p-value 0.xxxx 
1 Results are obtained from a linear model with correlated errors employed for the Primary Analysis of 
the Primary Endpoint. 
 
2Predicted means are calculated for an exemplary subject assuming that he/she is albuminuric from the 
Joslin site, with serum uric acid posited at 6 mg/dL, HbA1c at 8%, baseline AER geometric mean at 80 
mg/min and baseline iGFR at 70 ml/min/1.73 m2. Covariate values for exemplary subject were set close 





S_2. iGFR time trajectory estimated from repeated iGFR measurements. mITT Analysis 
Set.1 
 





iGFR slope (95% CI) x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect (difference 
between Allopurinol versus 
Placebo iGFR slopes) (95% CI) 
x.xx (x.xx, x.xx) 
p-value 0.xxxx 
1 iGFR slope estimates and 95%CIs are obtained from a linear mixed-effects model for repeated iGFR 
measures. Fixed effects included stratifying variables: serum uric acid, HbA1c, study center, time since 
randomization in days, time by treatment group interaction, albuminuria status, baseline AER geometric 
mean (at Visits 3 and 4 combined) expressed on log to base 10 scale, baseline iGFR. Random effects 
included subject-specific intercepts and slopes for iGFR 
 
S_3. eGFR at 4 months after randomization (Visit 7). mITT Analysis Set1. 
 





eGFR Predicted Means at Visit 
7 (95% CI)2 
x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect at Visit 7 
(95% CI) 
x.xx (x.xx, x.xx) 
p-value 0.xxxx 
1Results are obtained using a linear model with independent residual errors. Fixed effects, included 
stratifying variables (serum uric acid, HbA1c, study center), treatment group,   albuminuria status, 
baseline AER geometric mean (at Visits 3 and 4 combined) expressed on log to base 10 scale, baseline 
eGFR.  
 
2Predicted means are calculated for an exemplary subject assuming that he/she is albuminuric from the 
Joslin site, with serum uric acid posited at 6 mg/dL, HBA1c at 8%, baseline AER geometric mean at 80 
mg/min and baseline eGFR at 70 ml/min/1.73 m2. Covariate values for this exemplary subject were set 














S_4. eGFR time trajectory. mITT Analysis Set.1 
 





eGFR slope (95% CI) x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect (difference 
between Allopurinol versus 
Placebo eGFR slopes) (95% 
CI) 
x.xx (x.xx, x.xx) 
p-value 0.xxxx 
1 eGFR slope estimates and 95% CIs are obtained from a linear mixed-effects model for repeated eGFR 
measures. Fixed effects included stratifying variables: serum uric acid, HbA1c, study center, time since 
randomization in days, time by treatment group interaction, albuminuria status, baseline AER geometric 
mean (at Visits 3 and 4 combined) expressed on log to base 10 scale, baseline eGFR. Random effects 
included subject-specific intercepts and slopes for eGFR. 
 
S_5. Time to serum creatinine doubling or ESRD.  mITT Analysis Set.  
 





N (%)  of subjects with 
doubled serum creatinine or 
ESRD during the course of the 
study  
Xx (xx.x%) Xx( xx.x%)  





1based on Cox Proportional Hazards Model. Fixed effects, included stratifying variables (serum uric 
acid, HbA1c, study center), treatment group, albuminuria status, baseline AER geometric mean (at 
Visits 3 and 4 combined) expressed on log to base 10 scale, and baseline iGFR. 
 
 S_6. Urinary AER at the end of the wash-out period. mITT Analysis Set.1 
 





Predicted Urinary AER at the 
end of the wash-out   period 
(95% CI)2 
x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect at Visit 17 
expressed as % difference 
(95% CI) 
xx.x% (xx.x%, xx.x%) 
p-value 0.xxxx 
1Results are obtained using a linear model with independent residual errors. The dependent variable is 
geometric mean of two AER measures obtained at Visit 17 expressed on log base to 10 scale. Fixed 
 
effects, included stratifying variables (serum uric acid, HbA1c, study center), treatment group,   
albuminuria status, baseline AER geometric mean (at Visits 3 and 4 combined) expressed on log to base 
10 scale, and baseline iGFR.  
 
2Predicted urinary AER values are calculated using antilog transformation for an exemplary subject 
assuming that he/she is albuminuric from the Joslin site, with serum uric acid posited at 6 mg/dL, 
HbA1c at 8%, baseline AER geometric mean at 80 mg/min and baseline iGFR at 70 ml/min/1.73 m2. 
Covariate values for exemplary subject were set close to their median values for continuous variables 
and most frequent categories for categorical variables 
 
S_7. Urinary AER during the last three months of the treatment period (Visits 15 and 
16). mITT Analysis Set.1 
 





Predicted Urinary AER during 
the last three months of the 
treatment period (95% CI)2 
x.xx (x.xx, x.xx) x.xx (x.xx, x.xx) 
Treatment Effect expressed as 
% difference (95% CI) 
between treatment groups 
xx.x% (xx.x%, xx.x%) 
p-value 0.xxxx 
1Results are obtained using a linear model with independent residual errors. The dependent variable is 
geometric mean of two AER measures obtained at Visits 15 and 16 expressed on log base to 10 scale. 
Fixed effects, included stratifying variables (serum uric acid, HbA1c, study center), treatment group,   
albuminuria status, baseline AER geometric mean (at Visits 3 and 4 combined) expressed on log to base 
10 scale, and baseline iGFR.  
 
2Predicted urinary AER values are calculated using antilog transformation for an exemplary subject 
assuming that he/she is albuminuric from the Joslin site, with uric acid posited at 6 mg/dL, glycated 
hemoglobin at 8%, baseline AER geometric mean at 80 mg/min and baseline iGFR at 70 ml/min/1.73 
m2. Covariate values for this exemplary subject were set close to their median values for continuous 
variables and most frequent categories for categorical variables 
 
S_8. Time to fatal or non-fatal cardiovascular events. mITT Analysis Set. 
 





N (%) of Subjects with fatal  or 
non-fatal CVD during the 
course of the study 
xx (xx.x%) xx (xx.x%) 





1based on Cox Proportional Hazards Model. Fixed effects, included stratifying variables (serum uric 
acid, HbA1c, study center), treatment group, albuminuria status, baseline AER geometric mean (at 
Visits 3 and 4 combined) expressed on log to base 10 scale, and baseline iGFR. 
 
7.2. Analyses of Safety Outcomes. 
 
Table S1: Subjects Discontinuing Study Medication because of Severe Adverse Events 









# of subjects d/c treatment 
X X X 
# of Subjects 
X X X 
% of subjects d/c treatment 




treatment by treatment group 
 










# of SAE's 
X X X 
# of subjects with SAE's 
X X X 
# of Subjects 
X X X 
SAE's per subject 
x.xx x.xx x.xx 
% of subjects with SAE's 
x.x% x.x% x.x% 
p-value* 
x.xxxx 
*p- percentage of subjects with SAEs 
by treatment group 
 
Table S3:  Summary of Number of SAEs per Subject in the Pre- and Post-
Randomization Periods for Non-Randomized and Randomized Subjects. mITT Subjects. 
 






1 N (xx.x%) N (xx.x%) N 
2 N (xx.x%) N (xx.x%) N 
3 N (xx.x%) N (xx.x%) N 
>4 N (xx.x%) N (xx.x%) N 
Relative Risk (95% CI)1 x.xx (x.xx, x.xx)  
 






p-value1 0.xxxx  
1Based on Poisson regression model with treatment as a covariate and follow-up time as an offset 
 












N N N 
Gastrointestinal N N N 
Hepatic N N N 
Immunological N N N 
Infectious N N N 
Metabolic N N N 
Miscellaneous N N N 
Neoplastic N N N 
Neurological N N N 
Nutritional N N N 
Orthopedic N N N 
Pulmonary N N N 
Surgical N N N 
Total SAEs N N N 
Total Subjects with SAEs N N N 
Total Subjects Randomized N N N 
% with SAEs xx.x% xx.x% xx.x% 
p-value* 0.xxxx 
*p-
SAEs by treatment group 
 
Table S5: Subjects Discontinuing Study Medication because of Adverse Events by 









# of subjects d/c treatment 
X X X 
# of Subjects 
X X X 
% of subjects d/c treatment 




treatment by treatment group 
 
 










# of AE's 
X X X 
# of subjects with AE's 
X X X 
# of Subjects 
X X X 
AE's per subject 
x.xx x.xx x.xx 
% of subjects with AE's 




by treatment group 
 
Table S7:  Summary of Number of AEs per Subject in the Pre- and Post-Randomization 
Periods for Non-Randomized and Randomized Subjects. mITT Subjects. 
 






1 N (xx.x%) N (xx.x%) N 
2 N (xx.x%) N (xx.x%) N 
3 N (xx.x%) N (xx.x%) N 
>4 N (xx.x%) N (xx.x%) N 
Relative Risk (95% CI)1 x.xx (x.xx, x.xx)  
p-value1 0.xxxx  
1Based on Poisson regression model with treatment as a covariate and follow-up time as an offset 
 












N N N 
Gastrointestinal N N N 
Hepatic N N N 
Immunological N N N 
Infectious N N N 
Metabolic N N N 
Miscellaneous N N N 
Neoplastic N N N 
Neurological N N N 
Nutritional N N N 
Orthopedic N N N 
Pulmonary N N N 
Surgical N N N 
Total AEs N N N 
Total Subjects with AEs N N N 
Total Subjects Randomized N N N 
% with AEs xx.x% xx.x% xx.x% 
p-value* 0.xxxx 
*p-
by treatment group 
 









Stevens-Johnson Syndrome (SJS) x/x (xx%) x/x (xx%) x/x (xx%) 
Skin rash  x/x (xx%) x/x (xx%) x/x (xx%) 
Subjects with SJS or skin rash X x N 
Total Subjects with Skin reaction 
Assessed 
x x N 








Figure S1a.  Time to first SAE during On-Study Drug Period, with Log-Rank Test to 
Compare Treatment Groups. mITT Subjects. 
Kaplan Meier curve of time from randomization to first SAE by treatment group; subjects 
censored at earliest of death, withdrawal, lost-to-follow-up, or end of study medication 
 
Y axis label = % of Subjects (100%, 90%,  
X axis label = Time (days) post-randomization (0, 6, 12, 18, 24, 30, 36 months) 
 
Figure S1b.  Time to first SAE during Off-Study Drug Period, with Log-Rank Test to 
Compare Treatment Groups.  mITT Subjects. 
Kaplan Meier curve of time from end of study medication to first SAE by treatment group; 
subjects censored at earliest of death or completion of study (withdrawal, lost-to-follow-up or 
end of study).     
 
X axis label = Time (months) post-treatment (0, 6, 12, 18, 24, 30, 36 months) 
 
Additional Descriptive Statistics by Treatment Group 
Table A1a.  Comparison of iGFR by Treatment Groups.  mITT Analysis Set. 
 









iGFR at Visit 4 
     N 
     Mean (SD) 
     Min, Max 
     N missing 
iGFR at Visit 11 
     N 
     Mean (SD) 
     Min, Max 
     N missing 
iGFR at Visit 16 
     N 
     Mean (SD) 
     Min, Max 
     N missing 
iGFR Visit 17 
     N 
     Mean (SD) 
     Min, Max 
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APPENDIX I. Study Objective, Study Design, Outcomes & Statistical 
Analysis and Data Management Sections from Protocol  
 
In this appendix, selected sections (from protocol, version 9, approved by DSMB on August 
16th, 2016) are included for reference. The following sections/figures from the study protocol 
are included:  
 
 2. Study Objective 
 3. Study design 
 7.1. Primary outcomes 
 7.2. Secondary outcomes 
 Schedule of events (original figure on p. 27 in the study protocol) 
 9. Safety assessments 
 10. Adverse Event Reporting 
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1. Overview  
DESIGN:  
 Multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial. 
 N=530 total number of subjects  
 
STUDY POPULATION: 
 Type 1 Diabetes  
 Inclusion/Exclusion Criteria listed in the Study Protocol   
 
STUDY TREATMENTS: 
 Oral allopurinol or placebo administered for 3 years followed by a 2-month drug 
washout 
 
PRIMARY OUTCOME MEASURE: 
 iGFR at the end of the 2-month wash-out period following the 3-year intervention 
 
STATISTICAL ANALYSIS PLAN: 
 This plan will be finalized prior to the database lock and unblinding of treatment groups
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2. Schema  
Figure 2.1. PERL Study Schema 
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3. Rationale for Adjustments of Statistical Analysis Plan as 
Compared to Protocol (Version 10, approved by DSMB on March 6, 
2018)  
Changes from the protocol-specified definitions of aims, outcomes, and statistical analytical 
approaches are outlined below. These changes reflect internal discussions since the initiation of 
the study that have not been incorporated as protocol amendments, but were discussed during the 
preparation of the Statistical Analysis Plan. These changes and the rationale for their 
implementation are documented herein and represent changes made prior to the database lock 
and unblinding of the study. 
 
3.1. Specifying primary and secondary estimands 
RATIONALE: 
In the study protocol, we describe the analysis populations (section 11.1) and methods to deal 
with incomplete data (section 11.5); however, we do not explicitly specify estimands of 
(August 30, 2017) and to elucidate the target of our 
research questions, we formally define estimands that have led us to our decisions in terms of 
conducting the study and selecting analytical approaches. 
3.2. Simplified model for the primary efficacy analysis using a multiple 
imputation approach 
RATIONALE: 
The primary efficacy analysis presented in Section 11.3 of the study protocol was based on a 
linear model for correlated errors using all available iGFR measures (including those at 
baseline, 80, 156, and 164 weeks, respectively) as the dependent variable. 
 
To effectively address missing values in baseline covariates and the need to consider iGFR 
values that were not measured after end stage renal disease (ESRD)  as an unfavorable 
outcome, direct likelihood based methods are difficult to implement. For this reason, we have 
decided to perform the primary efficacy analysis using a multiple imputation (MI) approach. 
To perform the MI analysis, we define both imputation and substantive models. We note that 
in the substantive model, iGFR at baseline is no longer included as a dependent variable.  
 
PROTOCOL:   
correlated errors with general/unstructured covariance matrix using all available iGFR 
measures (including those at baseline, 80, 156, and 164 weeks, respectively) as the dependent 
 
SAP:   
using a multiple imputation 
approach with a substantive model defined by means of a linear model for correlated errors 
with general/unstructured covariance matrix using all post-baseline iGFR measures (including 
those at  80, 156, and 164 weeks, respectively) as the dependent variable. 
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3.3. Revised cut-points for variables used in subgroup analyses 
RATIONALE: 
The protocol specified cut-points for subgroup analyses based on educated guesses about the 
distributions of variables. After investigating baseline distributions of age and AER in pooled 
analyses, we changed the cut-points for these variables to achieve better balance in subgroup 
sample size: (1) for age from 40 to 50 years (median age 52 years), (2) for iGFR from 70 to 60 
ml/min/1.73 m2 and (3) for AER from 300 to 30 mg/24h (median AER 42 mg/24h). 
 
PROTOCOL: 
To investigate the possible presence of heterogeneity in the response to allopurinol, subgroup 
analyses (based on the primary efficacy analysis described in section 11.3, with the inclusion 
of an interaction term of the treatment group by the subgroup variable) will be performed by 
yrs.), ,  and >70 ml/ min/1.73m2) AER at 
hr.), and . 
 
SAP: 
To investigate the possible presence of heterogeneity in the response to allopurinol, subgroup 
analyses (based on the primary efficacy analysis described in section 11.3, with the inclusion 
of an interaction term of the treatment group by the subgroup variable) will be performed by 
  and >60 ml/ min/1.73m2) AER at 
baseline 30 and > 30 mg/24 hr.), and . 
3.4. Calculations of visit windows for the analytical dataset 
RATIONALE: 
Per-protocol windows for scheduling Visits 6-16 are calculated relative to the Visit 5 date. In 
early versions of the Study Protocol (versions 5.0 and 6.0), randomization was performed at a 
study visit (Visit 5) and consequently the visit date and randomization date were equivalent. 
Starting with Study Protocol, version 7.0, Visit 5 became a phone call visit and randomization 
did not necessarily occur on the date of the phone call. For analytical purposes (see SAP 
Section 6.3), visit windows will be calculated relative to randomization date.  
 
PROTOCOL: 
Visit 1 will be considered as Time 0 for scheduling Visits 2-5, Visit 5 will be considered as 
Time 0 for scheduling Visit 6-16, Visit 16 as Time 0 for scheduling Visit 17. 
 
SAP: 
Visit 1 will be considered as Time 0 for scheduling Visits 2-5, Visit 5 will be considered as 
Time 0 for scheduling Visit 6-16, Visit 16 as Time 0 for scheduling Visit 17. 
For analytical purposes, the randomization date will be considered as Time 0 for calculating 
windows for Visits 6-16. 
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3.5. Additional analysis assessing an effect of post-randomization serum 
uric acid changes on iGFR values at Visit 17 
RATIONALE: 
Following internal discussion on the importance of the relationship between serum uric acid 






Details are provided in SAP Section 6.8.4. 
 
3.6. Additional analysis assessing treatment effect on time to 40% eGFR 
decrease    
RATIONALE: 
Following internal discussion on the importance of the recently proposed measure of kidney 






Details are provided in SAP Section 6.8.5. 
 
3.7. Additional analysis assessing time to doubling of serum creatinine, end-
stage renal disease (ESRD), or cardiovascular/renal death 
RATIONALE: 
Following internal discussion on the importance of the recently proposed measure of kidney 
decline, namely using cardiovascular/renal death as part of the composite endpoint definition, 






Details are provided in SAP Section 6.8.6. 
 
3.8. Modifying definition of per-protocol analysis set  
RATIONALE: 
Following internal discussion we modified the per-protocol definition as follows. 
 
PROTOCOL: 
 Per Protocol:     The per protocol population will exclude subject as well as 
data points for which the cumulative exposure to the study medication from 
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randomization to that time point was less than 80% of the theoretical full exposure 
(see Section 11.1 in the protocol). 
 
SAP: 
 Per Protocol:   whom 
the average drug exposure was less than 80% (see Section 11.1 in the protocol). 
 
4. Study Aim  
The study aim is to determine whether lowering serum UA by means of oral allopurinol is 
effective in preventing or slowing decline of renal function in T1D patients with history and/or 
presence of microalbuminuria or moderate macroalbuminuria, or with ongoing GFR loss 
regardless of history or presence of albuminuria, who have only mildly or moderately impaired 
kidney function. 
5. Study Estimands 
This section describes the primary and secondary estimands for corresponding endpoints and 
variables of interest. We follow ICH-E9 (R1) recommendations and specify estimands in terms 
of four attributes defining the treatment effect of interest: 
 
A1. The target population 
A2. The variable (or endpoint) to be obtained for each patient that is required to 
address scientific question of interest 
A3. Strategies for addressing intercurrent events 
A4. The population summary for the variable (endpoint), that provides a basis for 
a comparison between treatment conditions. 
 
In Table 5.1. we include various intercurrent events that occurred in the PERL study and  divide 
them into three groups, based on their implications for subsequent data collection of the endpoint 
of interest. 
 
Table 5.1. Groups of intercurrent (IC) events in PERL study 
 
Group of IC events IC event Implications for Post-IC data 
Group A Non-adherence to study drug 
schedule 
Post-IC data are collected, but their 
interpretation may be affected 
depending on  the estimand of interest Permanent discontinuation of 
study drug 
Use of prohibited medication 
Missed scheduled visit 
Group B ESRD treatment (hemodialysis 
or transplant for ESRD subjects) 
Post-IC data do not contain any relevant 
information about estimands of interest 
and for this reason they  are not 
collected 
Group C Early discontinuation from the 
study 
Post-IC data cannot be collected 
Terminal event, i.e. death 
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5.1. Primary estimand for iGFR at Visit 17 endpoint 
This is the de-facto (effectiveness) estimand of the primary endpoint  iGFR at Visit 17   
that quantifies a treatment effect due to the initially randomized treatments as actually taken, 
i.e., the treatment of allopurinol versus placebo without a confounding effect of  treatment for 
ESRD subjects. The four attributes of this estimand are as follows:
A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
A2. The variable (or endpoint): The primary endpoint is the measured glomerular filtration 
rate (GFR) based on plasma disappearance of non-radioactive iohexol (iGFR) at the end of the 
2-month wash-out period (Visit 17 at Week 164) following the 3-year intervention. The 
rationale of measuring the primary outcome at the end of the wash-out period is to test 
allopurinol for durable effects on the natural history of kidney disease, independent from any 
transient, hemodynamic effect that the medication may have on GFR. iGFR is calculated from 
blood samples drawn at baseline and 120, 150, 180, 210, and 240 minutes after an i.v. bolus of 
iohexol, adjusting for body surface area. 
A3. Strategies for different groups of IC events: Depending on IC event group membership 
(see Table 5.1), the variable of interest, in this case iGFR values, collected after an IC event in 
- Group A will be considered as directly interpretable. Effectively, IC events in this 
group are ignored, which is consistent with the ITT principle. 
- Group B are assumed to follow a hypothetical scenario, in which variable of interest 
after developing ESRD takes on biologically plausible values that are not confounded 
by IC event i.e. by ESRD treatment. 
- Group C are assumed to conform to a hypothetical scenario in which post-IC values 
of the variable of interest (or endpoint) have a similar distribution to other non-ESRD 
subjects 
A4. Population summary to compare treatments: Population-average treatment effect on iGFR 
at V17.  
 
5.2. Secondary estimands 
5.2.1. Estimand for iGFR at the end of the 3-year treatment period (Visit 16, before 
the washout) a secondary endpoint 
This is de-facto (effectiveness) estimand for the iGFR at Visit 16 endpoint with the 
following attributes: 
 
A1. Target population: T1D (inclusion/exclusion criteria specified in the Study Protocol) 
 
A2. Variable of interest (endpoint): iGFR calculated at the end of the 3-year intervention 
(at Visit 16, last visit before washout) 
 
A3. Strategies for different groups of IC events: The same as those used for primary 
estimand (see Section 5.1) 
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A4. Population summary to compare treatments: Population-average treatment effect on 
iGFR at V16  
 
5.2.2. Estimand for iGFR time trajectory estimated from repeated iGFR 
measurements 
This is de-facto (effectiveness) estimand for repeated iGFR measures with the following 
attributes: 
A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
 
A2. Variables of interest: Repeated measures of iGFR at Visits 11, 16, 17. 
 
A3. Strategies for different groups of IC events: The same as those used for primary 
estimand (see Section 5.1) 
 
A4. Population summary to compare treatments: Population-average treatment effect on the 
slope of iGFR trajectory    
 
5.2.3. Estimand for estimated Glomerular Filtration Rate (eGFR) at 4 months after 
randomization (Visit 7)  
This is de-facto (effectiveness) estimand for eGFR at 4 months after randomization with 
the following attributes: 
 
A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
 
A2. Variable of interest (endpoint): eGFR at 4 months after randomization as estimated 
from serum creatinine and cystatin C using the CKD-EPI SCr and the CKD-EPI SCr-
SCysC equations (Inker et al, 2012, Fan et al, 2015). This endpoint is employed to measure 
a transient, hemodynamic effect that the study medication may have on GFR.  
 
A3. Strategies for different groups of IC events: The same as those used for primary 
estimand (see Section 5.1) 
 
A4. Population summary to compare treatments: Population-average treatment effect on 
eGFR at 4 months after randomization. 
 
5.2.4. Estimand for estimated GFR (eGFR) time trajectory  
This is de-facto (effectiveness) estimand for eGFR trajectory with the following attributes: 
A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
A2. Variable of interest (endpoint): Repeated eGFR measures at all post-randomization 
visits (Visit 6 through 17) as estimated from repeated serum creatinine and cystatin C 
measurements using the CKD-EPI SCr and the CKD-EPI SCr-SCysC equations. 
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A3. Strategies for different groups of IC events: The same as those used for primary 
estimand (see Section 5.1) 
A4. Population summary to compare treatments: Population-average treatment effect on 
the slope of post-randomization eGFR trajectory    
5.2.5. Estimand for time to doubling of serum creatinine or end-stage renal disease 
(ESRD) 
This is de-facto (effectiveness) estimand for doubling of serum creatinine or developing 
ESRD with the following attributes. 
 
A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
 
A2. Variable of interest (endpoint): This secondary endpoint is defined as a composite of 
two events: (1) doubling to serum creatinine, and (2) ESRD.  Time to event is defined as 
time from randomization to the first event (one of the events defined above) or censoring 
(lost-to-follow-up, withdrawal, death, and study completion without experiencing the 
event).
A3. Strategies for different groups of IC events: Depending on IC event group membership 
(see Table 5.1) variable of interest/endpoint values, collected after IC event in 
       -    Group A will be considered as directly interpretable. Effectively IC events in this 
group are ignored, which is consistent with the ITT principle. 
       -    Groups B and C are assumed to conform a hypothetical scenario in which the 
variable of interest/endpoint values have a similar distribution to subjects not experiencing 
the IC event. 
A4. Population summary to compare treatments: Hazard ratio for allopurinol versus 
placebo.
5.2.6. Estimand for urinary AER at the end of the two-month wash-out period (Visit 
17) 
This is de-facto (effectiveness) estimand for AER at V17 with the following attributes. 
 
A1. Target population:  Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
 
A2. Variable of interest (endpoint): Geometric mean of two urinary AER measures 
obtained at Visit 17. 
 
A3. Strategies for different groups of IC events: Depending on IC event group membership 
(see Table 5.1) variable of interest/endpoint values, collected after IC event in 
       -    Group A will be considered as directly interpretable. Effectively IC events in this 
group are ignored, which is consistent with the ITT principle. 
       -    Groups B and C are assumed to conform a hypothetical scenario in which the 
variable of interest/endpoint values have a similar distribution to subjects not experiencing 
the IC event. 
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A4. Population summary to compare treatments: Population-average treatment effect on 
AER at V17 expressed as a ratio of geometric means. 
 
5.2.7. Estimand for urinary AER during the last three months of the treatment period 
(Visits 15 and 16) 
This is de-facto (effectiveness) estimand for AER at Visit 15 and 16 with the following 
attributes: 
 
A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
 
A2. Variable of interest (endpoint): Geometric mean of urinary AER measures at Visit 15 
and Visit 16.  
 
A3. Strategies for different groups of IC events: Depending on IC event group membership 
(see Table 5.1) variable of interest/endpoint values, collected after IC event in 
       -    Group A will be considered as directly interpretable. Effectively IC events in this 
group are ignored, which is consistent with ITT principle. 
       -    Groups B and C are assumed to conform a hypothetical scenario in which the 
variable of interest/endpoint values have a similar distribution to subjects not experiencing 
the IC event. 
 
A4. Population summary to compare treatments: Population-average treatment effect on 
AER during last three months of the treatment expressed as a ratio of geometric means. 
 
5.2.8. Estimand for the time to fatal or non-fatal cardiovascular events endpoint  
This is de-facto (effectiveness) estimand for fatal and non-fatal cardio-vascular events with 
the following attributes: 
 
 A1. Target population: Individuals with T1D meeting the inclusion/exclusion criteria 
specified in the Study Protocol. 
 
A2. Variable of interest (endpoint): This secondary endpoint is defined as a composite of 
multiple events: (1) Cardiovascular disease (CVD) death (ICD-10 code I10 to I74.9), (2) 
Myocardial infarction, (3) Stroke (ischemic or hemorrhagic), (4) Coronary artery bypass 
grafting, or (5) Percutaneous coronary intervention. Time to fatal or non-fatal 
cardiovascular events is defined as the time from randomization to the first event (one of 
the events defined above) or censoring (lost-to-follow-up, withdrawal, non-CVD death, and 
study completion without experiencing the event).
A3. Strategies for different groups of IC events: Depending on IC event group membership 
(see Table 5.1) variable of interest/endpoint values, collected after IC event in 
       -    Group A will be considered as directly interpretable. Effectively IC events in this 
group are ignored, which is consistent with ITT principle. 
       -    Groups B and C (except CVD death) are assumed to conform a hypothetical 
scenario in which variable of interest/endpoint values have similar distribution to subjects 
not experiencing IC event. 
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A4. Population summary to compare treatments: Hazard ratio for allopurinol versus 
placebo
6. Analytical Strategy 
In the initial analysis of the primary outcome we will present iGFR univariate statistics by 
Treatment Groups at each study visit (V4, V11, V16 and V17). 
 
level to be used at the final analysis will be 0.05 for the primary endpoint. All other secondary 
outcomes will also be tested at the 0.05 level, with no adjustment for multiplicity. Many of the 
models used in the analyses include baseline covariates, such as stratifying variables (serum uric 
acid (sUA), HbA1C, clinical site), iGFR, albuminuria status (subjects who qualified by ACR or 
AER or were albuminuric at baseline vs. subjects who qualified by eGFR slope and were 
normoalbuminuric at baseline), AER, and time, and time by treatment interaction. If there are 
problems with fitting these models, due, for example, to lack of convergence to optimal values, 
covariates will be eliminated from the models in the following order: baseline AER, albuminuria 
status, serum uric acid (sUA), HbA1c, and clinical site. More detailed information about these 
covariates is included in Section 6.4.  
 
6.1. Study populations 
Two study populations will be defined for the purpose of data analysis: 
 Intention to Treat (ITT): The ITT analysis set consists of all subjects enrolled in 
PERL, randomized to study medication. 
 Per Protocol: The per protocol analysis set will consist of a subset of ITT subjects.   
The per protocol population will exclude subjects with major protocol deviations 
(defined as receiving the wrong study medication) as well as subjects for whom the 
average drug exposure is less than 80% (see Section 11.1 in the protocol). 
 
To account for missing values in any specific analysis, all subjects meeting the study 
population definitions will be included and analyzed using (1) multiple imputation techniques 
(see Section 6.4), or (2) appropriate analytical approaches that allow for missing values under 
plausible missing data mechanisms, such as linear mixed-effects models that allow values of 
the dependent variable to be missing under missing at random (MAR) mechanism.  
 
Long study follow-up results in missing values for the outcomes and precludes strict adhering 
to ITT principle. To mitigate this issue we will follow four strategies proposed by I.R. White 
et al (2011): 
1. Attempt to follow up all randomized participants, even if they withdraw from 
allocated treatment. 
2. Perform a main analysis of all observed data that are valid under a plausible 
assumption about missing data. 
3. Perform sensitivity analyses to explore the effect of departures from the assumptions 
made in the main analysis. 
4. Account for all ITT study population participants, at least in the sensitivity analyses.  
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6.2. Blinded data review 
Prior to unmasking the study and starting any formal analysis, data will be reviewed in a 
blinded fashion by computing summary statistics for primary and secondary outcomes, and 
baseline covariates. This will allow the identification of unusual values and/or patterns of 
missing values for key variables that need to be queried. In addition, such blinded data review 
will allow the writing committee to assess the format of data presentation. Note that the 
blinded data review incorporates real data but random treatment assignment (i.e., investigators 
do not receive data summarized by actual treatment group, rather they review data on two 
randomly formed groups). All decisions will be made and documented in this SAP document 
prior to database lock and unblinding. 
 
6.3. Visit windows 
To provide scheduling flexibility to study sites and participants, visits were required to occur 
within a protocol-defined window rather than on a specific date. The protocol-defined visit 
windows are summarized in the tables 6.3.1 and 6.3.2 below. For analytic purposes, the visit 
windows defined in the protocol will be expanded in order to eliminate gaps between them. 
This will ensure that all observations, including those that may have occurred outside a 
protocol-specified time window, will be associated with the most appropriate visit and 
therefore properly included in the analysis. If multiple observations occur within a window, 
the one closest to the visit target date will be utilized. If two observations are equi-distant 
from the target date, the first one will be utilized.  
 
As iGFR is the primary and key secondary endpoint, the protocol allowed for repeats of the 
iGFR procedure in order to achieve qualified iGFR values. Also, the procedure required a 
longer visit, so it was more difficult to schedule. Thus, we allowed wider windows for iGFR 
visits (V11, V16 and V17) to ensure that all qualified iGFRs are analyzed. In addition to avoid 
over-writing iGFR visits with a non-iGFR (V6-V10, V12-V15) visit, and vice-versa the 
aforementioned procedure will be performed separately for non-iGFR (Table 6.3.1) and iGFR 
visits (Table 6.3.2). 
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Per protocol Target Date 
window in weeks 
Upper Boundary 
of Window (Week, 





(in weeks)  
Visit Windows relative to Randomization Date 
 
Visit 6 0 4 [3-5] 10   5 
Visit 7  10  16 [14-20] 24  17 
Visit 8 24 32 [30-34] 40  32 
Visit 9 40 48 [46-50] 56  48 
Visit 10 56 64 [62-66] 72  64 
Visit 12 88 96 [94-98] 104  96 
Visit 13 104 112 [110 -114] 120 112 
Visit 14 120 128 [126 -130] 135 128 
Visit 15 135 142 [140 -146] 150 142 
 
All intervals (target dates and lower/upper window boundaries) for visits 6 through 16 are 
calculated relative to the randomization date. The interval for Visit 17 is calculated relative to 
Visit 16. Most post-randomization visits are 16 weeks apart, with the exception of Visits 6 and 
7 and Visits 16 to visit 17. For the purpose of selected analyses (sections 6.7.2 and 6.7.4) 
involving multiple imputations, we included in the last column of Tables 6.3.1 and 6.3.2 a 
time since randomization associated with a corresponding visit window. Entries in this 
column are based approximately on the mid-points between target dates. 
 








Per protocol Target 
Date window in weeks 
Upper Boundary of 
Window (Week, 











53 80 [78-84] 97 80 
Visit 16 
(iGFR) 
149 156 [154 -160] 178 164 
Visit Window relative to V16  
Visit 17 
(iGFR) 
0 8 [6 12] 20 174 
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6.4. Baseline covariates  
The following is a description of the baseline covariates that will be used in the various 
analyses outlined in the remainder of Section 6.  
 Stratifying variables 
 serum uric acid (sUA) at baseline with 2 levels  
 glycated hemoglobin (HbA1c) at baseline with two levels  
 clinical site/study center with 16 levels (based on main sites with satellite sites 
collapsed into main sites) 
 Baseline iGFR measured at Visit 4 
 Baseline eGFR measured at Visit 4 
 Treatment group with two levels (Allopurinol, Placebo) 
 Albuminuria status with 2 levels (subjects who qualified by ACR or AER or were 
albuminuric at baseline vs. subjects who qualified by eGFR slope and were 
normoalbuminuric at baseline) 
 Baseline AER geometric mean  (at Visits 3 and 4 combined) expressed on log to base 
10 scale 
 
As of Dec. 17, 2018, we have complete data available for baseline serum uric acid, treatment 
group, and study center. The number of missing values for the other baseline covariates is 1 
for iGFR, 2 for HbA1c, and 17 for albuminuria status. Missing baseline data will be imputed 
according to the approach described in Section 6.5. When creating covariates for analytical 
and imputation purposes, we will aggregate clinical sites with a small number of randomized 
subjects, such as Edmonton (site #11, n=3) and Vancouver (site #16, n=11) will be combined 
with Calgary (site #10, n=20) in the same geographic region. Similarly, Spokane (site #15, 
n=5) will be combined with  Seattle (site #13, n=35).   
 
6.5. Missing values 
Missing values both for baseline characteristics and for outcomes/endpoints of interest are 
inevitable, especially in studies with longer follow-up. To effectively address missing values 
that occurred for baseline covariates and for post-randomization variables of interest, and the 
necessity to consider post-ESRD iGFR values as an unfavorable outcome, models involving 
direct likelihood methods are difficult to implement. For this reason, we will perform the 
analyses using a multiple imputation (MI) approach consisting of three steps: 
 
Step 1. Using an imputation model, create multiple datasets with missing values imputed  
Step 2. Fit substantive models described in Sections 6.6 and 6.7 using imputed datasets 
created in Step 1 
Step 3. For each substantive model, combine the results obtained in Step 2 for the inference 
. 
 
To create imputed datasets in Step 1, we will employ multivariate imputation by means of fully 
conditional specification (FCS) method introduced by van Buuren et al, 2006. This method is 
especially attractive in our case because it handles non-monotone patterns of missingness, and 
arbitrary types of imputed variables, i.e. both continuous and categorical. The imputation model 
will include baseline covariates listed in Section 6.4. In addition, to make imputation model more 
general than substantive models, we will include HbA1c at Visit 1 and geometric mean of AER 
at Visit 3 and 4 expressed on logarithmic base to 10 scale predictive of other baseline covariates. 
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We will also include eGFR at all post-randomization visits, i.e., Visit 6-17, iGFR at Visits 11, 16 
and 17, AER at Visits 15, 16 and 17 expressed on logarithmic base to 10 scale. Imputation of 
baseline variables will be performed starting with variables having the lowest number of missing 
values. Variables measured longitudinally, i.e., eGFR and iGFR, will also be modeled 
sequentially in order determined by visit number. To preserve different response patterns in the 
study treatment groups (i.e., treatment group by study visit interaction) imputations will be 
performed separately in each group. Resulting data will consist of 25 imputed datasets. We note 
that the FCS method imputes data under the missing at random (MAR) assumption, e.g., the 
probability that the iGFR/eGFR value is missing depends on observed rather than unobserved 
values of the variable. Although we consider the MAR assumption to be sensible for our study, it 
does not apply for post-ESRD iGFR/eGFR values. To model post-ESRD eGFR measures as a 
deviation from the MAR assumption, we will impute these values using a controlled imputation 
technique, specifically the delta-adjustment approach ( ). This technique 
will impute post-ESRD eGFR values on average at 7 ml/min/1.73m2, with a small variation 
around it, that is consistent with: (1) attributing to missing post-ESRD eGFR values the value 
, (2) assigning a biologically acceptable value, and (3) 
including the feature of ESRD. We note that eGFR measures are taken at every 
visit and are used to determine time of developing ESRD. For this reason pre-ESRD eGFR 
values are highly predictive of post-ESRD iGFR values. In addition, we note that post-ESRD 
iGFR and eGFR values lie in a very narrow range and they are effectively interchangeable. For 
these reasons, we will impute post-ESRD iGFR values by using corresponding post-ESRD eGFR 
imputed values as a proxy. We note that the imputation of eGFR and iGFR values for subjects 
who did not develop ESRD and have low values to start with may lead to imputed values lower 
than 15 ml/min/1.73m2, which is biologically implausible. For this reason, imputed values of 
eGFR and iGFR for subjects who did not develop ESRD will be truncated at 15 ml/min/1.73m2. 
Similarly, log(AER) base 10 imputed values for these subjects will be truncated at a lower limit 
of detection of -0.60206 (= log10(0.25)).   
 
6.6. Analysis for the primary estimand 
In this Section we describe primary and secondary analyses aligned with the primary estimand 
defined in Section 5.1. These models will be employed as substantive models (see Step 2 of 
multiple imputation approach described in Section 6.5). 
6.6.1. Primary analysis for the primary estimand 
The goal of the primary analysis for the primary estimand is to test the null hypothesis of 
the difference in means between treatment arms in the primary endpoint (iGFR at the end 
of the 2-month wash-out period [Visit 17] following the 3-year intervention) being equal to 
zero. The analysis will be performed in a multiple imputation framework on the intention-
to-treat (ITT) population and will employ a linear model for correlated errors with 
general/unstructured covariance matrix (Molenberghs and Verbeke, 2005; Galecki and 
Burzykowski, 2013) as a substantive model. For each time t ( ) corresponding to 
post-randomization iGFR visits, i.e. visits V11 (80 weeks), V16 (156 weeks), and V17 (164 
weeks after randomization) the model equation is specified as: 
 
 
where  is the value of iGFR at time  for subject  ( ). Fixed effects 
 for  denote visit-specific intercepts and treatment effects.  is 
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treatment group (equal to 1 for the allopurinol and 0 for placebo). Stratifying variables 
(serum uric acid, HbA1c, study center), and baseline covariates: albuminuria status, AER, 
iGFR for subject  are included in a vector  of  covariates  and associated 
fixed effects are stored in vector . We assume that residual errors   
( for subject  are normally distributed with zero mean and 3x3 
general/unstructured variance-covariance matrix. The model specified in (6.1) will yield 
the estimates of visit-specific treatment effects for all three visits V11, V16 
and V17. In the context of the primary analysis of the primary endpoint, we are interested 
in parameter , representing treatment effect at Visit 17 adjusted for stratifying variables 
and baseline covariates. The Kenward-Roger approximation will be used to estimate 
denominator degrees of freedom.  
 
Estimand Primary estimand defined in Section 5.2.1 
Analysis Primary Analysis of the Primary Endpoint: iGFR at the end of the 2-month wash-
out period (Visit 17) 
Analysis Set ITT Population 




iGFR measured at Visits V11 (80 weeks) , V16 (156 weeks) and V17 (164 weeks 
after randomization) 
  
Model Fixed effects:  
 Visit-specific intercepts corresponding to V11, V16, V17 
 Visit-specific treatment effects corresponding to V11, V16, V17 
 Stratifying variables: sUA, HbA1c, study center  
 Albuminuria status with 2 levels  
 Baseline AER geometric mean  (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR  
Results  Least square iGFR means at Visit 17 by treatment group.  
 Estimate of treatment effect at Visit 17 adjusted for baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
We will assess the impact of deviation from the MAR assumption on the robustness of the 
results through a sensitivity analysis. For the primary estimand, it will be performed within 
the same multiple imputation framework; however we will employ marginal delta-adjusted 
method and apply it to Visit 17 with adjustments in allopurinol arm increasing by one unit 
of iGFR value until the MAR results are overturned, that is, we will use so called tipping 
point approach titch, 2014).   
6.6.2. Secondary analysis for the primary estimand 
The following secondary analyses will be performed to assess how alternative assumptions 
of the primary endpoint (as defined above) and alternative approaches for handling missing 
data may affect the conclusions of the analysis: 
 
1. Analysis of covariance using iGFR values at Visit 17 as the dependent variable and 
treatment effect as a covariate of primary interest. The same baseline covariates, as in 
the primary analysis of the primary endpoint, stored in vector  (see Equation. 6.1) 
will be used in the model. 
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2. Performing an analysis identical to the primary one (same endpoint and substantive 
model) using the per-protocol analysis set rather than the ITT analysis set. 
 
6.7. Analyses for secondary estimands 
In this section we present analyses aligned with secondary estimands defined in section 5.2. 
Analyses will be performed using the multiple imputation technique, except those involving 
time-to event endpoints (sections 6.7.5, 6.7.8). 
 
6.7.1. iGFR at the end of the 3-year treatment period (Visit 16, before the washout)  
In this section we describe the analysis (estimator) aligned with the estimand for iGFR at 
the end of the 3-year treatment period (Visit 16, before the washout) endpoint defined in 
Section 5.2.1. 
 
The least square means at Visit 16, estimate of treatment effect at Visit 16 adjusted for 
baseline covariates, their 95% confidence interval and P-value will be obtained as part of 
the primary analysis of the primary estimand (Equation (6.1) in section 6.1.1). In the 
context of this secondary endpoint, we are interested in the fixed effect , which 
represents the treatment effect at Visit 16 adjusted for stratifying variables and baseline 
covariates.To assess the hemodynamic/transient effect of the allopurinol, we will estimate 
the contrast  between the treatment effect at Visit 16 (before washout) compared 
to that at Visit 17 (after washout). 
 
6.7.2. iGFR time trajectory estimated from repeated iGFR measurements 
This analysis is aligned with the estimand defined in Section 5.2.2 
Estimand See section. 5.2.2 for definition 
Analysis Analysis of the Secondary Endpoint: iGFR time trajectory estimated from 
repeated iGFR measurements. 
Analysis Set ITT Population 




iGFR measured at Visits V11 (80 weeks) , V16 (156 weeks) and V17 (164 weeks 
after randomization)  
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group 
 Time since randomization (in years) associated visit windows defined in 
section 6.3 
 Time by treatment group interaction  
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR 
 
Subject-specific random effects 
 Random intercept for iGFR 
 Random slope for iGFR  
Results  iGFR slope estimates and 95%CIs by treatment group  
 Estimate of a treatment effect measured as a difference between average 
slopes of iGFR versus time for allopurinol and placebo groups adjusted 
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for stratifying variables and baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
6.7.3. eGFR at 4 months after randomization (Visit 7) 
Estimand See section 5.2.3 for definition 
Analysis Analysis of the Secondary Endpoint: eGFR at 4 months after randomization 
(Visit 7). 
Analysis Set ITT Population 
Methods Linear model using multiple imputation technique. 
Dependent 
Variable 
eGFR measured at Visit V7 (16 weeks after randomization) 
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline eGFR 
Results  Least square  eGFR means at Visit 7 by treatment group.  
 Estimate of treatment effect at Visit 7 adjusted for stratifying variables 
and baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 
 
6.7.4. eGFR time trajectory  
Estimand See section 5.2.4 for definition 
Analysis Analysis of the Secondary Endpoint: eGFR time trajectory estimated from 
repeated eGFR measurements using multiple imputation technique.. 
Analysis Set ITT Population 




Post-randomization eGFR measured from  Visits V6 through V17 
  
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group 
 Time since randomization in  (in years) associated visit windows 
defined in section 6.3 
 Time by treatment group interaction  
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline eGFR 
 
Subject-specific random effects 
 Random intercept for eGFR 
 Random slope for eGFR  
Results  eGFR slope estimates and 95%CIs by treatment group  
 Estimate of a treatment effect measured as a difference between average 
eGFR versus time slopes for allopurinol and placebo groups adjusted for 
stratifying variables and baseline covariates 
 95% confidence interval for treatment effect 
 P-value for treatment effect 




6.7.5. Time to serum creatinine doubling or ESRD 
Estimand See section 5.2.5 for definition 
Analysis Set ITT Population  
Methods  Proportional hazards model for interval censored data. 
Dependent 
Variable 
Time to composite endpoint of serum creatinine doubling or ESRD 
Proportional 
Hazards Model 
Fixed effects associated with:    
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR 
Results  N(%) of subjects with doubled serum creatinine or ESRD during the 
course of the study  
 Hazard ratio of allopurinol to placebo 
 95% confidence interval for hazard ratio 
 P-value for treatment effect 
  
6.7.6. Urinary AER at the end of the wash-out period 
Estimand See section 5.2.6 for definition 
Analysis Set ITT Population 
Methods Linear model using multiple imputation technique. 
Dependent 
Variable 
Two AER measures obtained at Visit 17 and summarized using the geometric 
mean expressed on logarithm base to 10 scale 
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  Predicted urinary AERs at Visit 17 by treatment group obtained by 
antilog transformation applied to corresponding least square means   
 Estimate of treatment effect at Visit 17 expressed on percent change 
scale using antilog transformation. 
 95% confidence interval for treatment effect expressed on percent 
change scale using antilog transformation. 
 P-value for treatment effect 
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6.7.7. Urinary AER during the last three months of the treatment period (Visits 15 
and 16) 
Estimand See Section 5.2.7 for definition 
Analysis Set ITT Population 
Methods Linear model using multiple imputation technique. 
Dependent 
Variable 
Two AER measures obtained at Visit 15 and 16 are summarized using the 
geometric mean expressed on logarithmic scale 
Model Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  Predicted AERs at the end of treatment period by treatment group 
obtained by antilog transformation applied to corresponding least square 
means.  
 Estimate of treatment effect at the end of treatment period adjusted for 
baseline covariates expressed on percent change scale using antilog 
transformation. 
 95% confidence interval for treatment effect expressed on percent 
change using antilog transformation. 
 P-value for treatment effect 
 
6.7.8. Time to fatal or non-fatal cardiovascular events 
Estimand See Section 5.2.8 for definition 
Analysis Set ITT Population  
Methods Cox proportional hazards model. 
Dependent 
Variable 
Time to composite endpoint: fatal or non-fatal cardiovascular events 
Cox Model Fixed effects:   
 Fixed effects associated with:  
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log base to 10 scale 
 Baseline iGFR 
Results  N(%) of subjects with fatal or non-fatal cardiovascular events during the 
course of the study 
 Hazard ratio of allopurinol to placebo 
 95% confidence interval for hazard ratio 
 P-value for treatment effect 
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6.8. Other analyses 
6.8.1. Subgroup analyses 
To investigate the possible presence of heterogeneity in the response to allopurinol, 
subgroup analyses (based on the primary efficacy analysis described in subsection 6.6.1, 
with the inclusion of appropriate interaction terms with the subgroup variable) will be 
performed by  
 0 ml/min and > 60). 
ml/min/1.73m2 0 mg/24 hr), and albuminuria status (subjects 
who qualified by ACR or AER or were albuminuric at baseline vs. subjects who did qualify 
by eGFR slope and were normoalbuminuric at baseline). 
 
An example of such subgroup analysis for age groups 0 yrs) is provided below. 
Similar to Equation (6.1) for each time t ( ), corresponding to visits V11, V16, 
V17, we specify the model: 
 
 
where  is the value of iGFR at time  for subject  ( ). Fixed effects 
 for  denote visit-specific intercepts, treatment effects, age effects 
and age by treatment interactions, respectively.   is treatment group (equal to 1 for the 
allopurinol and 0 for placebo).  0 yrs). Stratifying 
variables, and baseline covariates albuminuria status, AER, iGFR for subject  are included 
in a vector of covariates  and associated fixed effects are stored in vector . We assume 
that residual errors  ( for subject  are normally distributed with zero mean 
and 3x3 general/unstructured variance-covariance matrix. The model specified in (6.2) will 
yield the estimates of visit-specific treatment by age interaction effects for all 
three visits V11, V16 and V17. In the context of subgroup analysis, we are interested in 
, which represents treatment by age interaction at Visit 17 adjusted for baseline 
covariates. 
 
Analysis Subgroup Analysis of the Primary Endpoint: iGFR at the end of the 2-month wash-
out period (Visit 17) by Age group 
Analysis Set ITT Population 
Methods Linear model for repeated measures with correlated errors 
Dependent 
Variable 
iGFR measured at Visits V11 (80 weeks) , V16 (156 weeks) and V17 (164 weeks 
after randomization) 
Model Fixed effects:  
 Visit-specific intercepts, age effects, treatment effects and age by 
treatment interaction effects 
 Stratifying variables: sUA, HbA1c , Study center 
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed on 
log base to 10 scale 
 Baseline iGFR 
Results  Estimate of age by treatment interaction at Visit 17 adjusted for baseline 
covariates 
 95% confidence interval for age by treatment effect interaction at Visit 17 
 P-value for treatment effect 
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6.8.2. Analyses of safety outcomes 
Safety measures are assessed during three periods of the study: run-in (Visits 1-5), on-
treatment (after Visit 5 through Visit 16), and off-treatment washout (after Visit 16 through 
Visit 17). Safety will be summarized overall (treatment and off-treatment combined) and 
by period, depending on the safety outcome of interest during that period.  
 Percentage of subjects with and number of SAEs, time to first SAEs during on-treatment 
period and overall by MedDRA System Organ Class and by MedDRA Preferred Term 
Categories. 
 Percentage of subjects with and number of permanent discontinuations of study 
medication because of adverse effects on-treatment period and overall. 
 Percentage of subjects with and number of AEs, overall and by severity and by 
relatedness to study medication during on-treatment period and overall. 
 Percentage and number of subjects with skin rash during on-treatment period and overall. 
 
For dichotomous safety outcomes, the proportion of subjects experiencing adverse 
outcomes (AEs, SAEs) will be summarized by treatment group and compared by means of 
odds ratios and 95% CIs. Poisson regression models will be used for safety outcomes (e.g., 
SAEs and AEs) with multiple recurrences per patient, with the logarithm of the period of 
observation from the time of study medication used as the offset. Time to first SAE will be 
analyzed using Kaplan-Meier methods to estimate the SAE-free distributions for each 
treatment group. This analysis will employ the ITT analysis set. No imputation for missing 
data will be used. 
   
6.8.3 Analyses of other measures 
In addition to primary, secondary, and safety measures, the following additional outcomes 
will be analyzed to help with the interpretation of study results:  
 
 Descriptive statistics for body weight, blood pressure, serum creatinine, HbA1c, and 
serum uric acid at each post-baseline visit and their changes from baseline, by treatment 
group in the ITT population. No imputation for missing data will be employed. 
 Percentage of subjects receiving adequate study medication exposure (i.e., allopurinol or 
placebo) independent of adverse events. This is defined as the actual total dose during the 
156-week dosing period, as determined from the dispensed dosage and pill counts, divided 
by the expected total dose defined by the eGFR-adjusted protocol-described dosing 
regimen, without consideration for temporary or permanent discontinuations or reductions 
owing to adverse events. The proportion of subjects receiving the presumed adequate study 
medication exposure is defined as the number of subjects who had at least 80% and no 
more than 120% of the intended study medications during the entire dosing period, 
independent of adverse events, among all randomized subjects. No imputation for missing 
data will be employed. 
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6.8.4. Analysis of the effect of post-randomization sUA changes on iGFR value at Visit 
17 
 
The analysis outlined below will be performed using linear model with correlated errors. In 
addition to fixed effects associated with baseline covariates, we will include fixed effects 
associated with visit-specific effects of another covariate, namely the average sUA change 
from baseline over the initial post-randomization period (Visits 6-10) on iGFR values. We 
note that this covariate is created based on sUA values that precede iGFR measures (our 
dependent variable) and in this way we attempt to mitigate the impact of the bidirectional 
relationship between concurrent measures of sUA and iGFR. 
 
Analysis Analysis of the effect of post-randomization average changes of 
sUA values (V6-V10) relative to sUA at baseline on iGFR 








iGFR measured at Visits V11 (80 weeks), V16 (156 weeks) and 
V17 (164 weeks after randomization)  
Model Fixed effects associated with:  
 Visit-specific intercepts corresponding to V11, V16, V17 
 Visit-specific effects of sUA change on iGFR at V11, V16, 
V17 
 Stratifying variables: sUA, HbA1c, study center 
 Albuminuria status at baseline with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) 
expressed on log to base 10 scale 
 Baseline iGFR 
Results  Estimate of an effect of an average sUA changes from 
baseline on iGFR value at Visit 17,  adjusted for stratifying 
variables and baseline covariates 
 95% confidence interval for sUA changes effect 
 P-value for sUA changes effect  
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6.8.5. Time to 40% eGFR decrease 
Analysis Analysis of time to 40% eGFR decrease from randomization 
Analysis Set ITT Population  
Methods Proportional hazards model for interval censored data. 
Dependent 
Variable 




Fixed effects associated with:    
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) 
expressed on log to base 10 scale 
 
Results  N(%) of subjects with 40% eGFR decrease during the 
course of the study  
 Hazard ratio of allopurinol to placebo 
 95% confidence interval for hazard ratio 
 P-value for treatment effect 
  
6.8.6. Time to doubling of serum creatinine, end-stage renal disease (ESRD), or 
cardiovascular/renal death  
Variable of interest (endpoint) is defined as a composite of three events: (1) doubling to 
serum creatinine, (2) ESRD, or (3) cardiovascular/renal death. Time to event is defined as 
time from randomization to the first event (one of the events defined above) or censoring 
(lost-to-follow-up, withdrawal, death other than due to cardiovascular/renal cause, and 
study completion without experiencing the event).
 
Analysis Set ITT Population  
Methods Proportional hazards model for interval censored data. 
Dependent 
Variable 
Time from randomization to composite endpoint of serum creatinine doubling, 
ESRD or cardiovascular/renal death 
Proportional 
Hazards Model 
Fixed effects associated with:    
 Stratifying variables: sUA, HbA1c, study center 
 Treatment group   
 Albuminuria status with 2 levels  
 Baseline AER geometric mean (at Visits 3 and 4 combined) expressed 
on log to base 10 scale 
 Baseline iGFR 
Results  N(%) of subjects with doubled serum creatinine, ESRD or 
cardiovascular/renal death during the course of the study  
 Hazard ratio of allopurinol to placebo 
 95% confidence interval for hazard ratio 
 P-value for treatment effect 
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6.9. Model assumptions and alternative analyses 
Model assumptions will be thoroughly checked for individual and systematic departures, 
using informal, e.g. inspection of residuals, and formal methods such as methods based on 
likelihood displacement. If individual outliers are detected, their influence will be evaluated 
using influence diagnostics methods based on comparing estimates from models fitted to data 
with and without outlying values. Whenever we are not successful in fitting the parametric 
model (linear or non-linear), then non-parametric analyses and/or transformation of the 
variables involved in the analysis will be considered. 
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APPENDIX I. Study Objective, Study Design, Outcomes & Statistical 
Analysis and Data Management Sections from Protocol  
In this appendix, selected sections (from protocol, version 10, approved by DSMB on March 6th, 
2018) are included for reference. The following sections/figures from the study protocol are 
included:  
 
 2. Study objective 
 3. Study design 
 7.1. Primary outcomes 
 7.2. Secondary outcomes 
 Schedule of events (original figure on p. 27 in the study protocol) 
 9. Safety assessments 
 10. Adverse event reporting 
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Summary of Changes to the Statistical Analysis Plan 
The first statistical analysis plan for the PERL status (version dated February 22, 2017) was 
prepared for inclusion as an appendix to the NIH application for renewal of the grant supporting 
this clinical trial.  This SAP was approved by the Steering Committee but was not reviewed by 
NIDDK or the PERL DSMB.  
A subsequent SAP version (dated May 14, 2019) was prepared as the trial was approaching 
completion. This was reviewed and approved by the Steering Committee, NIDDK, and the 
DSMB.  The main changes in this version as compared to the previous one (dated February 22, 
2017 were): 
 Section 3. Rationale for adjustments of the SAP as compared to Protocol 
 Addition and justification of several adjustments to the analyses detailed in the 
Protocol (v10, dated March 6, 2018).  
 Section 5. Study estimands 
 Re-framing of data analysis in terms of Study estimands , in order to follow 
ICH-E9 (R1) recommendations. 
 Section 6. Analytical strategy: 
 6.1. Study population.  
 Revision of the definition of the ITT and per protocol populations. 
 Addition of details regarding the imputation methods. 
 6.3. Visit Windows.  
 Specification of wider windows for V11, V16, and V17 to ensure that all 
iGFR are analyzed.  
 Addition of procedure to avoid temporal overlap of iGFR and non-iGFR 
visits.    
 Creation of separate tables for non-iGFR and iGFR visit windows (Tables 
6.3.1 and 6.3.2). 
 Addition of Time since randomization attributed to visit window  to 
tables with visit windows. 
 Section 6.4. Baseline Covariates 
 Addition of methods to impute missing values for baseline covariates. 
 Section 6.5 (New) Missing values 
 Description of methods to account for missing values.  
 Section 6.6. Analysis of the primary estimand 
 Miscellaneous changes to make the analysis consistent with the re-framing 
in terms of Study estimands and for the more detail description of 
imputation methods. 
 Addition of the tipping point sensitivity analysis to check the robustness of 
the MAR assumption.  
 Section 6.7. Analysis of secondary estimands 
 Miscellaneous changes to make analysis consistent with the re-framing in 
terms of Study estimands and for the more detail description of imputation 
methods. 
 Section 6.8. Other analyses 
 Section 6.8.1 changes in cut-offs for stratified analyses to make them 
consistent with changes made in Section 3. 
 Section 6.8.2. Addition of details about the metrics used to evaluate safety. 
 Section 6.8.3. Addition of details on the additional analyses introduced in 
Section 3 (effect of post-randomization serum urate changes on iGFR at 
V17, effect of allopurinol on time to 40% eGFR decrease, effect of 
allopurinol on composite of serum creatinine doubling, ESRD, and 
CVD/renal death.  
 Section 7. Mock Tables and Figures  Deleted. 
 
Minor revisions were made to the SAP on August 3, 2019, right before the lock of the study 
database. These changes included: 
 Section 6. Analytical Strategy 
 Section 6.4. Baseline Covariates  
 Clarification about the aggregation of sites with small numbers of 
randomized individuals within the baseline covariate  
 Section 6.5. Missing values 
 Clarification about the imputation of eGFR and iGFR values in subjects 
who started with low GFR values and did not develop ESRD.  
 6.6. Analysis of the primary estimand. 
 Addition of Kenward-Roger approximation to estimate degrees of 
freedom. 
 
  
